---
title: "Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Product information and disease description"
description: "Formulary evidence on Emiltatug ledadotin (Emi-Le, XMT-1660) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Product information and disease description. Covers Product description and Place of product in therapy. 261 evidence topics quoted from 106 sources."
canonical: "https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/product-information-and-disease-description"
published: "2026-09-17T22:01:26-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: development and regulatory status as of November 2026

Emiltatug ledadotin (Emi-Le, XMT-1660) is investigational and has no marketing approval in any jurisdiction. It is being studied in NCT05377996, a phase 1/2 first-in-human trial with dose escalation, dose expansion, and a phase 2 part (EMBLEM-1) in aggressive adenoid cystic carcinoma (ACC); the registry record was last updated in June 2026 with status recruiting, an estimated enrollment of 360 participants, and an estimated primary completion date of February 2027. The FDA granted Breakthrough Therapy designation on or before 12 May 2026 for locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation. Earlier FDA Fast Track designations cover advanced or metastatic triple-negative breast cancer and HER2-low or HER2-negative breast cancer after a topoisomerase-1 inhibitor ADC. EMBLEM-1 enrolls participants with measurable aggressive ACC confirmed by histopathologic criteria (solid or basaloid histology, or high-grade transformation) and by clinical phenotype (progression within 3 years or extrapulmonary metastasis), and tests 80 mg/m2 every 4 weeks (capped at 160 mg) with objective response rate as the primary endpoint. Day One's February 2026 annual report described the phase 1b objective as defining a dose and clinical activity for a potential single-arm registrational trial for accelerated approval or a randomized trial; after the ASCO 2026 phase 1 data, the sponsor described EMBLEM-1 as a “pivotal Phase 2 study”. On 19 October 2026, Servier announced that the “first patients have been dosed in the pivotal Phase 2 cohort (EMBLEM-1)”. In the same annual report, Day One stated that it “may seek” orphan drug designation for Emi-Le; no orphan drug designation, biologics license application, regulatory submission, submission timing, or launch date was identified. Under the acquisition agreement, contingent payments are tied to first dosing in a registrational ACC-1 trial by 31 December 2027 and FDA approval in ACC-1 by 31 December 2030.

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996); [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [Servier EMBLEM-1 first patients dosed announcement (2026)](https://servier.mediaroom.com/2026-10-19-Servier-Announces-First-Patients-Dosed-in-Pivotal-Phase-2-EMBLEM-1-Cohort-Evaluating-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [Mersana Therapeutics Fast Track announcement (2025)](https://www.biospace.com/press-releases/mersana-therapeutics-announces-additional-fda-fast-track-designation-granted-to-emiltatug-ledadotin-xmt-1660); [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm); [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="topic-2.1.1-2"></a>

##### United States: Breakthrough Therapy designation in ACC with solid histology or high-grade transformation

> “Servier today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Emi-Le, an investigational ADC directed against B7-H4, a well-characterized target in certain cancers.”
> “The breakthrough therapy designation has been granted for treatment of patients with locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation.”
> “Emi-Le is currently under clinical development in the U.S. for potential use in aggressive ACC and other cancers”

Source: [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC)

<a id="topic-2.1.1-3"></a>

##### United States: Fast Track designations in breast cancer

> “The new Fast Track designation is for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 (HER2) low (IHC 1+ or IHC 2+/ISH–) or HER2-negative (IHC 0) disease, including triple-negative breast cancer (TNBC), who have received a prior topoisomerase-1 inhibitor ADC.”
> “The FDA previously granted Fast Track designation to Emi-Le for the treatment of adult patients with advanced or metastatic recurrent TNBC.”

Source: [Mersana Therapeutics Fast Track announcement (2025)](https://www.biospace.com/press-releases/mersana-therapeutics-announces-additional-fda-fast-track-designation-granted-to-emiltatug-ledadotin-xmt-1660)

<a id="topic-2.1.1-4"></a>

##### Current development phase: phase 1/2 trial with the EMBLEM-1 phase 2 part

> “A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors”
> “The study will have three parts. The first part called Dose Escalation, will find out how much Emi-Le should be given to participants. The second part called Dose Expansion, will use the dose found in the first part to find out how safe Emi-Le is and if it works to treat solid tumors. The third part, the Phase 2 part of the trial, called EMBLEM-1, will find out if Emi-Le works to treat aggressive Adenoid Cystic Carcinoma and continue to check how safe Emi-Le is.”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.1.1-5"></a>

##### EMBLEM-1: population, dose, and endpoints

> “The phase 2 EMBLEM-1 study (NCT05377996), a continuation of the phase 1 program, is enrolling patients with aggressive ACC and measurable disease per RECIST v1.1, with the phenotype confirmed by both histopathologic criteria (solid/basaloid histology or HGT) and clinical phenotype (progression within 3 years or extrapulmonary metastasis).”
> “The dosing regimen is emiltatug ledadotin 80 mg/m² (capped at 160 mg) Q4W, with ORR as the primary end point and DOR, DCR, PFS, overall survival, and safety as secondary end points.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.1-6"></a>

##### Planned registration pathway

> “The objective of the Phase 1b study is to define an optimized dose and to define clinical activity in one or more histologically defined tumor types for a potential single-arm registrational trial for accelerated approval or randomized trial.”
> “We plan to move Emi-Le forward in ACC, an aggressive cancer with a well-defined patient population and high unmet need, most often arising from the salivary gland.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

> “These encouraging data at ASCO indicate strong promise to support a population distinctly in need of effective therapies and will help inform the pivotal Phase 2 study we will undertake in a larger set of participants.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-2.1.1-7"></a>

##### Contractual development milestones set at the time of acquisition

> “$4.00 per CVR, payable upon occurrence of the first dosing of the first participant in a Registrational Clinical Trial (as defined in the CVR Agreement) of Emi-Le for adenoid cystic carcinoma type 1 (“ACC-1”) on or before December 31, 2027;”
> “$9.00 per CVR, payable upon the occurrence of Regulatory Approval (as defined in the CVR Agreement) by the FDA for Emi-Le indicated for use in ACC-1 on or before December 31, 2030;”

Source: [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="topic-2.1.1-8"></a>

##### Orphan drug designation

> “We may seek orphan drug designation for tovorafenib in additional geographies or indications, or for Emi-Le and DAY301 or any product candidates we may develop in the future.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.1.1-9"></a>

##### Regulatory status

No evidence found.

<a id="topic-2.1.1-10"></a>

##### First participants dosed in the pivotal phase 2 EMBLEM-1 cohort, October 2026

> “Servier today announced the first patients have been dosed in the pivotal Phase 2 cohort (EMBLEM-1) of a Phase 1/2 study of Emiltatug Ledadotin (Emi-Le) in solid tumors.”
> “Emi-Le is under evaluation in an ongoing Phase 1/2 clinical trial and has not been approved by the FDA, and its safety and effectiveness have not been established.”

Source: [Servier EMBLEM-1 first patients dosed announcement (2026)](https://servier.mediaroom.com/2026-10-19-Servier-Announces-First-Patients-Dosed-in-Pivotal-Phase-2-EMBLEM-1-Cohort-Evaluating-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma)

<a id="topic-2.1.1-11"></a>

##### Launch

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Servier

> “Servier today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Emi-Le”

Source: [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC)

> “Servier today announced promising new Phase 1 clinical data for Emi-Le, an investigational antibody drug conjugate (ADC) directed against B7-H4”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name and development codes

> “Emiltatug ledadotin (Emi-Le; DAY501 or XMT-1660) is a B7-H4-directed ADC with a site-specific conjugated auristatin F-HPA microtubule inhibitor payload at a homogenous DAR6 via a fully synthetic linker framework using the GlycoConnect® technology.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

> “The company also announced that the World Health Organization has approved emiltatug ledadotin (abbreviated as Emi-Le) as XMT-1660’s international nonproprietary name (INN).”

Source: [Mersana Therapeutics Fast Track announcement (2025)](https://www.biospace.com/press-releases/mersana-therapeutics-announces-additional-fda-fast-track-designation-granted-to-emiltatug-ledadotin-xmt-1660)

<a id="topic-2.1.2.1-3"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

###### Therapeutic class

> “Emi-Le (XMT-1660) is a B7-H4-directed ADC with an auristatin F-HPA microtubule inhibitor payload.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-2.1.2.1-5"></a>

###### Originator: Mersana Therapeutics

> “Our two clinical-stage product candidates are emiltatug ledadotin (XMT-1660), which we refer to as Emi-Le, and XMT-2056. Emi-Le is a B7-H4-targeting Dolasynthen ADC designed with a precise, target-optimized DAR of 6 that we are investigating in a Phase 1 clinical trial that is currently enrolling patients with various tumors, including breast, endometrial and ovarian cancers, as well as adenoid cystic carcinoma type 1, or ACC-1.”

Source: [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm)

<a id="topic-2.1.2.1-6"></a>

###### Acquisition of Mersana Therapeutics by Day One Biopharmaceuticals

> “Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it has entered into a definitive merger agreement with Day One Biopharmaceuticals (“Day One”), pursuant to which Day One would acquire Mersana, through a tender offer followed by a second step merger”

Source: [Mersana Therapeutics Day One merger announcement (2025)](https://www.globenewswire.com/news-release/2025/11/13/3187105/0/en/Day-One-Biopharmaceuticals-to-Acquire-Mersana-Therapeutics.html)

> “All of the conditions of the tender offer having been satisfied, Day One accepted for payment all such tendered shares, and following a statutory merger under Section 251(h) of the Delaware General Corporation Law on January 6, 2026, Mersana became a direct wholly owned subsidiary of Day One.”
> “Through this acquisition, Day One has added a second novel ADC to the company’s clinical pipeline.”

Source: [Day One Biopharmaceuticals acquisition completion announcement (2026)](https://www.globenewswire.com/news-release/2026/01/06/3213738/0/en/Day-One-Completes-Acquisition-of-Mersana-Therapeutics.html)

<a id="topic-2.1.2.1-7"></a>

###### Acquisition of Day One Biopharmaceuticals by Servier

> “Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share.”
> “In addition to tovorafenib, which is being investigated in additional indications, Day One’s pipeline includes Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) and DAY301, a targeted therapy in rare cancers.”

Source: [Servier acquisition completion announcement (2026)](https://servier.com/en/newsroom/servier-completes-the-acquisition-of-day-one-biopharmaceuticals/)

<a id="topic-2.1.2.1-8"></a>

###### Current trial sponsor

| Field | Quoted record |
| --- | --- |
| Lead sponsor | “Day One Biopharmaceuticals, Inc.” |
| Organization study ID | “MER-XMT-1660-1” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.1.2.1-9"></a>

###### Manufacturing

> “We do not own or operate and currently have no plans to establish any current good manufacturing practices, or cGMP, compliant manufacturing facilities. We currently rely, and expect to continue to rely, on external Contract Manufacturing Organizations, or CMOs, for the manufacture of product to support our activities through regulatory approval and commercial manufacturing, as well as to support our manufacturing obligations under our current collaborations.”

Source: [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Route of administration in clinical trials

> “Emi-Le will be administered through a vein in your arm or port catheter (intravenously)”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.1.2.2-2"></a>

###### Dosing units used in clinical trials

> “Across dose escalation and backfill, eligible pts received Emi-Le at doses of 7.2–115 mg/m2 IV per Q3W or Q4W cycle.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-2.1.2.2-3"></a>

###### Formulation, vial strength, and storage

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Product price

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Mechanistic classification

> “XMT-1660 is a site-specific DS DAR 6 ADC that induced complete tumor regressions in xenograft models of breast and ovarian cancer as well as in a syngeneic breast cancer model that is refractory to PD-1 immune checkpoint inhibition.”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification or ATC code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Summary: indication under development

Emiltatug ledadotin has no approved indication. The FDA Breakthrough Therapy designation covers locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation. The phase 1 ACC cohort enrolled adults whose disease met a clinical definition of aggressive ACC and/or a molecular definition (activating NOTCH1 to NOTCH4 mutations, c-Myc positivity, or p63-negative or low tumors). EMBLEM-1 requires both a histopathologic criterion (solid or basaloid histology, or high-grade transformation) and a clinical criterion (progression within 3 years or extrapulmonary metastasis), which matches the stricter definition used in the post hoc analysis of 32 evaluable participants presented at ASCO 2026. Positive B7-H4 expression is not listed as an EMBLEM-1 enrollment criterion in the sources identified; tissue is submitted for B7-H4 testing. The same trial also enrolled participants with breast, endometrial, and ovarian cancers, and two dose expansion cohorts enrolled participants with triple-negative breast cancer previously treated with a topoisomerase-1 inhibitor ADC.

Source: [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC); [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="topic-2.1.2.5-2"></a>

###### Indication named in the Breakthrough Therapy designation

> “It has also received Breakthrough Designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma with solid histology or high-grade transformation.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-2.1.2.5-3"></a>

###### Phase 1: eligibility definition of aggressive ACC

> “Eligibility criteria for ACC pts required features consistent with aggressive disease that included 1 of the following: 1) clinically aggressive phenotype, defined as < 3 years to recurrence/progression or de novo metastatic disease with atypical metastatic sites and solid tumor morphology, and/or 2) molecular features consistent with poor prognosis (activating NOTCH1–4 mutations or c-Myc positive or p63 negative/low per IHC).”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-2.1.2.5-4"></a>

###### Post hoc analysis and EMBLEM-1: clinicopathologic definition of aggressive ACC

> “For the post hoc analysis, a stricter clinicopathologic definition required both a histopathologic phenotype (solid/basaloid histology or HGT) and at least one clinical risk factor (progression within 3 years or extrapulmonary metastasis).”
> “Tissue is submitted for B7-H4 testing and molecular profiling.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.5-5"></a>

###### Other tumor types under study

| Field | Quoted record |
| --- | --- |
| Conditions | “Triple Negative Breast Cancer”, “Breast Cancer”, “Endometrial Cancer”, “Ovarian Cancer”, “Fallopian Tube Cancer”, “Primary Peritoneal Cavity Cancer”, “Adenoid Cystic Carcinoma” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

> “To that end, we continue to follow patients in our two dose expansion cohorts in patients with triple-negative breast cancer, or TNBC, who have received one to four prior treatment lines in the locally advanced or metastatic setting, including at least one prior topoisomerase-1 inhibitor, or topo-1, ADC.”

Source: [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Target: B7-H4

> “B7-H4 (VTCN1) is a member of the B7 immune checkpoint family with a distinct expression pattern from classical checkpoint pathways. It acts as an immunosuppressant that regulates the innate and adaptive immune systems and is associated with exclusion of T cells from the tumor microenvironment.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

> “Its expression in normal human tissue is generally reported to be limited, but it is highly expressed on multiple tumor types with high unmet need, including breast, endometrial and ovarian cancers and ACC-1.”

Source: [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Antibody: human IgG1 without B7-H4 function-blocking activity

> “The selected antibody (XMT-1604) is a human IgG1 kappa monoclonal antibody that specifically binds to human B7-H4 with sub nanomolar affinity and exhibits comparable binding profiles to recombinant B7-H4 from human, cynomolgus monkey, mouse, and rat (Supplementary Table S3).”
> “These data indicate that the B7-H4 antibody does not exhibit function-blocking activity.”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

<a id="topic-2.1.2.6.1-3"></a>

###### Dolasynthen platform and selection of drug-to-antibody ratio 6

> “To allow for ADC optimization for a given target antigen, we developed Dolasynthen (DS), a novel ADC platform based on the payload auristatin hydroxypropylamide, that enables precise DAR-ranging and site-specific conjugation.”
> “In the case of B7-H4, the site-specific DS DAR 6 ADC (XMT-1660) exhibited superior in vivo antitumor activity and noninferior in vitro, pharmacokinetics, and toxicology profiles relative to the DS DAR 2 and DF DAR 12 ADCs.”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

<a id="topic-2.1.2.6.1-4"></a>

###### Payload: auristatin F-HPA and controlled bystander effect

> “A distinguishing feature of the payload in the DF platform, auristatin F hydroxypropylamide (AF-HPA), is its controlled bystander effect. In general, bystander effect is the ability of an ADC to indirectly cause the death of antigen-negative cells; for instance, by the diffusion of payload delivered to antigen-positive cells into neighboring antigen-negative cells. In the case of DF, the ability of AF-HPA to diffuse into neighboring tumor cells is balanced by the intracellular conversion of AF-HPA to AF, a molecule that is highly active intracellularly and gets trapped in tumor cells because it is less membrane permeable and not a PgP substrate.”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

> “Dolasynthen utilizes the same proprietary auristatin anti-tubulin payload that was utilized in Dolaflexin.”
> “Moreover, because our auristatin payload targets tubulin, it is not dependent on the expression or mutational status of topoisomerase-1 or topoisomerase-2 enzymes, which we believe may allow it to avoid topo-1-related resistance mechanisms.”

Source: [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### B7-H4 expression and prognosis in ACC subtypes

> “ACC-I tumors overexpressed the immune checkpoint B7-H4, and the degree of immune exclusion was directly correlated with B7-H4 expression levels, an independent predictor of poor survival.”
> “B7-H4 is highly expressed in poor-prognosis ACC-I subtype and is a potential therapeutic target.”

Source: [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)

> “ACC-I, the most aggressive type of ACC, is characterized by solid histology, NOTCH1 mutation enrichment, early development of metastasis including to visceral organs and poor prognosis (median overall survival (mOS) = 3.4 ys).”
> “Notably, our RNA-seq analysis, revealed significant upregulation of B7-H4, an inhibitory immune checkpoint, particularly in ACC-I”
> “No other immune checkpoint proteins were expressed at significant levels in ACC.”

Source: [de Sousa and Ferrarotto (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584030/)

<a id="topic-2.1.2.6.2-2"></a>

###### B7-H4 expression by histologic subtype: 265-case immunohistochemistry cohort

> “We performed immunohistochemical analysis of five ADC targets (EGFR, TROP2, B7-H4, Nectin-4, and AXL) across 265 ACC cases (193 non-solid subtype and 72 solid subtype) and examined their expression in relation to clinicopathological features, histological subtypes, and prognosis.”
> “Conversely, B7-H4 and Nectin-4 showed moderate-to-high expression in 59% and 55% of the overall cohort, but were notably enriched in the aggressive solid subtype, with high expression observed in 66% and 75% of cases, respectively.”
> “High B7-H4 and Nectin-4 expression levels were independently associated with reduced overall survival (p < 0.05), whereas EGFR and TROP2 expression showed no significant prognostic value.”

Source: [Wang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320353/)

> “Notably, in adenoid cystic carcinoma, or ACC, 94% of tumors exhibit some level of expression and high B7-H4 expression is correlated with worse prognosis.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.1.2.6.2-3"></a>

###### Preclinical activity of XMT-1660 and relationship to B7-H4 expression

> “In a panel of 28 breast cancer PDXs, XMT-1660 demonstrated activity that correlated with B7-H4 expression.”
> “As expected, based on the targeted delivery mediated by an ADC, the activity of XMT-1660 correlated with target expression (Fig. 5B; Supplementary Fig. S9), which suggests that in the clinic, it may be possible to prospectively enrich for responders based on the expression of B7-H4.”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

<a id="topic-2.1.2.6.2-4"></a>

###### Preclinical B7-H4-directed ADC activity in ACC patient-derived xenografts (class evidence, AZD8205)

> “Two ACC-I/B7-H4-high PDXs obtained 90% complete responses to a single dose of AZD8205, but none were observed with isotype-conjugated payload or in an ACC-II/B7-H4 low PDX.”

Source: [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)

<a id="topic-2.1.2.6.2-5"></a>

###### Clinical relationship between dose, B7-H4 expression, and activity: all tumor types

> “Clinical activity was correlated with both dose and B7-H4 expression.”

Source: [Hamilton et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009)

<a id="topic-2.1.2.6.2-6"></a>

###### Clinical relationship between B7-H4 expression and activity: participants with ACC

> “The median B7-H4 tumor proportion score (TPS) was 77.5% (range, 2%-100%) among 40 evaluated patients, and 66.7% harbored activating NOTCH1-4 mutations.”
> “B7-H4 expression level did not clearly predict benefit.”
> “Some patients with expression as low as 2% have evidence of durable and deep responses”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.6.2-7"></a>

###### B7-H4 expression in tumor and normal tissue in the AZD8205 development program (class evidence, AZD8205)

> “To address this gap, we developed a validated IHC protocol (Supplementary Fig. S2) and used it to assess the expression of B7-H4 across a large panel of normal tissues and 2145 tumor samples across 15 indications.”
> “In contrast, B7-H4 was detected in a limited number of normal human tissues, such as fallopian tube, lung, breast, and prostate, and was generally found in <10% of the total cells in the sample, restricted toward ductal or tubular epithelium, and primarily located on the apical luminal membrane (Supplementary Table S3).”

Source: [Kinneer et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36355054/)

<a id="topic-2.1.2.6.2-8"></a>

###### Bystander killing and patient-derived xenograft activity of a B7-H4-directed topoisomerase I inhibitor ADC (class evidence, AZD8205)

> “AZD8205 was cytotoxic to the target-negative HT29-GFP cells only when in co-culture with the target-positive HT29-huB7-H4 cells (Fig. 3A), clearly demonstrating a bystander-killing effect.”
> “The antitumor activity of AZD8205 was evaluated in a panel of 26 TNBC PDX models that represent a range of B7-H4 staining intensity and heterogeneity (Fig. 4A) as was observed in the TNBC patient samples (Figs. 1C and 4B).”
> “Upon a single intravenous administration of 3.5 mg/kg AZD8205, the best response according to modified RECIST criteria was complete or partial response in 18 (69%), stable disease in 2 (8%), and progressive disease in 6 (23%; Fig. 4C).”
> “Seven of the seven RAD51-negative PDX models (100%) responded to 3.5 mg/kg AZD8205 treatment, and five of seven (71%) achieved complete response (Fig. 5A).”
> “These results indicate that the level of target expression needed for ADC activity is context dependent and that incorporation of warhead sensitivity biomarkers could further refine approaches for patient selection.”

Source: [Kinneer et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36355054/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Nonclinical pharmacokinetics: cynomolgus monkeys

> “The DAR 6 ADC (XMT-1660) and the DAR 2 ADC were evaluated at equal payload dose in a repeat-dose study in cynomolgus monkeys. Both ADCs exhibited comparable pharmacokinetics profiles, with comparable clearance rates and high stability in circulation, as indicated by the extremely low quantities of free payload (Fig. 3D).”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

<a id="topic-2.1.2.6.3-2"></a>

###### Nonclinical biodistribution of released payload: rats

> “These data demonstrate the comparable distribution of released drug between XMT-1660 and nonbinding control ADC, which suggests, based on this limited study, that the B7-H4-directed antibody component of XMT-1660 did not impact biodistribution. Moreover, no accumulation of the released drug was observed.”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

<a id="topic-2.1.2.6.3-3"></a>

###### Human pharmacokinetics: exposure, half-life, clearance, and immunogenicity

No evidence found.

Additional sources: [Mersana Therapeutics ASCO 2025 presentation (2025)](https://ir.mersana.com/static-files/9773978b-21fc-43cc-8529-2acba33cf29c)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Summary: safety profile in the phase 1 trial

No prescribing information, boxed warning, contraindication, or risk evaluation and mitigation strategy exists because emiltatug ledadotin is investigational. In the ASCO 2026 abstract safety set (221 participants, data cutoff 1 October 2025), the most common treatment-related adverse events were proteinuria (49.8%), transient AST increase (49.3%), and fatigue (41.2%); grade 3 AST increase and grade 3 proteinuria each occurred in 17.6%, and 3.6% discontinued treatment because of treatment-related adverse events. The oral presentation reported 180 participants with transient AST increase (56%), proteinuria (54%), fatigue (42%), and nausea (33%), with no grade 4 or 5 events. Among 48 participants with ACC, treatment-related adverse events led to dose reduction in 45.8% and dose delay in 56.3%, and proteinuria (characterized on biopsy as glomerular podocytopathy) was the leading cause of dose modification. After a protocol amendment that added monitoring and renal-protective medications, proteinuria-related dose reductions decreased from 38.9% to 20% and delays from 50.0% to 6.7% among participants with ACC. Neutropenia (2.2%), keratitis (3.9%), and peripheral neuropathy (2.8%) were reported at low rates. Severe adverse events observed with UpRi, an earlier Mersana ADC that used the same auristatin payload, included hemorrhage, proteinuria, pneumonitis, and death.

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="topic-2.1.2.7.1-2"></a>

###### Prescribing information, boxed warnings, contraindications, and REMS

Not applicable.

<a id="topic-2.1.2.7.1-3"></a>

###### Treatment-related adverse events: all enrolled participants, October 2025 data cutoff

> “As of October 1, 2025, 221 pts were dosed.”
> “For the safety set of 221 pts, Emi-Le was well tolerated with no new safety signals identified. The most common treatment-related adverse events (TRAEs) were proteinuria (49.8%), transient AST increase (49.3%), and fatigue (41.2%). The only Grade 3 TRAEs in ≥10% of pts were transient AST increase (17.6%) and proteinuria (17.6%). TRAEs leading to treatment discontinuation occurred in 3.6% of pts. No treatment-related deaths were reported.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-2.1.2.7.1-4"></a>

###### Treatment-related adverse events: ASCO 2026 oral presentation

> “The most common TRAEs were transient AST increase (56%) generally asymptomatic and reversible proteinuria (54%), predominantly low-grade fatigue (42%) and nausea (33%).”
> “The only Grade 3 TRAEs in ≥10% of pts were transient AST increase (20%) and proteinuria (23%). No Grade 4 or 5 TRAEs reported.”
> “TRAEs leading to treatment discontinuation occurred in 3.9% of patients and no treatment-related deaths were reported.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

> “Any-grade treatment-related adverse effects (TRAEs) occurred in 88.9% of all patients and 100% of those with ACC, and grade 3 TRAEs occurred in 51.1% and 79.2%, respectively. There were no grade 4 or 5 TRAEs and no treatment-related deaths.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.7.1-5"></a>

###### Treatment-related adverse events: earlier data cutoffs

> “As of the December 13, 2024 data cut date, the following TRAEs of any grade were observed in 10% or more of patients across the entire population or in one of three dose groups: AST increase, proteinuria, nausea, fatigue, pyrexia, decreased appetite, diarrhea, ALT increase, anemia, ALP increase, decreased platelet count, vomiting, arthralgia, constipation, hypophosphatemia, increased amylase and headache.”

Source: [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm)

> “As of the March 8, 2025 data cut date, the most common TRAEs of any grade across the entire patient population were transient aspartate aminotransferase, or AST, increase (44% of patients), generally asymptomatic and reversible proteinuria (40%), low-grade fatigue (33%) and generally low-grade nausea (31%). The only Grade 3 TRAEs in ≥5% or more of all patients were AST increase (17%), proteinuria (14%) and anemia (6%).”

Source: [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="topic-2.1.2.7.1-6"></a>

###### Proteinuria: characterization, dose modification, and mitigation in participants with ACC

> “TRAEs led to discontinuation in only 1 patient (2.1%), dose reduction in 45.8%, and dose delay in 56.3% of patients. Asymptomatic proteinuria, characterized on post hoc biopsy as glomerular podocytopathy without acute renal vascular injury, represented the leading cause of dose modification. After a protocol amendment introduced an updated monitoring and management plan, including renal-protective medications, proteinuria-related dose reductions decreased from 38.9% to 20% and delays from 50.0% to 6.7% among patients with ACC.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.7.1-7"></a>

###### Proteinuria at high doses: effect on response confirmation

> “At these high dose levels, objective responses in multiple evaluable patients with B7-H4 high tumors were not confirmed after protocol-mandated dose delays for proteinuria. Mersana is implementing proteinuria mitigation efforts and continues to explore higher doses in dose escalation and backfill cohorts to identify a second dose for the expansion portion of the trial.”
> “Across the entire enrolled patient population, TRAEs leading to discontinuation, dose reduction and dose delay were observed in 2.3%, 9.2% and 12.3% of patients, respectively.”

Source: [Mersana Therapeutics initial clinical data announcement (2025)](https://www.globenewswire.com/news-release/2025/01/10/3007493/0/en/Mersana-Therapeutics-Announces-Positive-Initial-Clinical-Data-from-Phase-1-Clinical-Trial-of-Emiltatug-Ledadotin-XMT-1660-Initiation-of-Expansion-in-Triple-Negative-Breast-Cancer.html)

<a id="topic-2.1.2.7.1-8"></a>

###### Aspartate aminotransferase elevation

> “The most common TRAEs were transient aspartate aminotransferase elevations, which resolved to baseline or grade 1 by the subsequent dose, with no hepatic failure or Hy's law observed; asymptomatic and reversible proteinuria; and predominantly low-grade fatigue and nausea.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.7.1-9"></a>

###### Hematologic, neurologic, ocular, and pulmonary toxicities associated with other ADCs

> “No observed dose-limiting treatment-related neutropenia, neuropathy, ocular toxicity, interstitial lung disease or thrombocytopenia.”

Source: [Hamilton et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009)

> “There was no alopecia and no interstitial lung disease or pneumonitis, and rates of cytopenias, peripheral neuropathy, keratitis, and ocular toxicity were low relative to other ADCs, according to Hanna. Neutropenia, keratitis, and neuropathy occurred in 2.2%, 3.9%, and 2.8% of all patients, respectively.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.7.1-10"></a>

###### Class and platform risks: severe adverse events with other ADCs using the same auristatin payload

> “Patients in our clinical trials of UpRi, for which we discontinued development in 2023 and which was developed using our Dolaflexin platform, experienced severe TRAEs including, without limitation, death, hemorrhage, aspartate aminotransferase, or AST, elevation, nausea, platelet count decrease (including thrombocytopenia), fatigue, anemia, pyrexia, alanine aminotransferase, or ALT, elevation, blood alkaline phosphatase/lactate dehydrogenase, or ALP/LDH, increase, proteinuria, vomiting, asthenia, diarrhea, headache, peripheral neuropathy, neutropenia and pneumonitis.”
> “We are currently conducting a Phase 1 clinical trial of Emi-Le, which was developed using our Dolasynthen platform and utilizes the same auristatin payload as UpRi and XMT-1592.”

Source: [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="topic-2.1.2.7.1-11"></a>

###### Nonclinical toxicology

> “Moreover, the ADCs exhibited comparable safety profiles which were consistent with AF-HPA–based ADCs (27).”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age, hepatic disease, and other eligibility restrictions in the phase 1/2 trial

| Criterion | Quoted record |
| --- | --- |
| Minimum age | “18 Years” |
| Performance status | “Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1” |
| Liver disease | “History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver diseases.” |
| Central nervous system metastases | “Untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis.” |
| Cardiovascular disease | “Clinically significant cardiovascular disease” |
| Ocular disease | “Active keratitis (inflammation of the cornea of the eye)” |
| Prior auristatin ADC | “Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.” |
| Prior B7-H4 therapy | “Prior B7-H4 targeted treatment.” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.1.2.8-2"></a>

###### Age and sex of participants with ACC

> “Of these, 35 pts had ACC, with a median of 1 prior line of therapy (range 0–3), median age 58 years, and 57% were female.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-2.1.2.8-3"></a>

###### Pediatric use, pregnancy and lactation, renal impairment, and hepatic impairment pharmacokinetics

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Emiltatug Ledadotin

<a id="topic-2.1.2.9.1-1"></a>

###### Protocol restriction: prior systemic anticancer therapy washout

> “Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy to the chest within 3 months of starting study treatment or to other anatomic sites within 14 days of starting study treatment.”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.1.2.9.1-2"></a>

###### Clinical drug interaction studies

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Emiltatug Ledadotin on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Clinical drug interaction studies

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Summary: dose levels and dose selected for phase 2

Dose escalation evaluated 7.2 to 115 mg/m2 per cycle on three schedules (every 4 weeks, every 3 weeks, and days 1 and 8 of a 28-day cycle). Participants with ACC received 57.4 to 89 mg/m2 per cycle every 3 or 4 weeks. The first expansion dose (Dose A) was 67.4 mg/m2 every 4 weeks, selected from the intermediate dose range (38.1 to 67.4 mg/m2); at doses at or above 76.2 mg/m2, proteinuria-related dose delays prevented confirmation of some responses. A second expansion dose (Dose B) used 44.5 mg/m2 on days 1 and 8 of the first 4-week cycle followed by 80 mg/m2 every 4 weeks, and an 80 mg/m2 every-4-week cohort was also evaluated. The dose selected for the EMBLEM-1 phase 2 part is 80 mg/m2 every 4 weeks, capped at 160 mg. No labeled dose, dose-adjustment table, or recommended dose for any approved use exists.

Source: [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm); [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010); [Hamilton et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009); [Mersana Therapeutics initial clinical data announcement (2025)](https://www.globenewswire.com/news-release/2025/01/10/3007493/0/en/Mersana-Therapeutics-Announces-Positive-Initial-Clinical-Data-from-Phase-1-Clinical-Trial-of-Emiltatug-Ledadotin-XMT-1660-Initiation-of-Expansion-in-Triple-Negative-Breast-Cancer.html); [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.10.1-2"></a>

###### Dose escalation: dose range, schedules, and dose groups

> “The dose escalation portion of the clinical trial evaluated doses ranging from 7.2 mg/m2 to 115 mg/m2, as well as the following dosing schedules: Q4W; once every three weeks; and on days 1 and 8 of a 28-day cycle.”
> “We analyzed initial trial data as of the data cut date across the entire trial population and in three dose groups: those in a “Subtherapeutic Dose Range” from 7.2 to 28.7 mg/m2 per cycle, an “Intermediate Dose Range” from 38.1 to 67.4 mg/m2 per cycle and a “High Dose Range” at or above 76.2 mg/m2 per cycle.”

Source: [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm)

<a id="topic-2.1.2.10.1-3"></a>

###### Phase 1: doses received by participants with ACC

> “Pts with ACC received Emi-Le at doses of 57.4–89 mg/m2 IV per Q3W or Q4W cycle.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-2.1.2.10.1-4"></a>

###### Initial expansion dose: 67.4 mg/m2 every 4 weeks

> “Based on these encouraging Emi-Le data at intermediate doses, Mersana has advanced a dose of 67.4 mg/m2 every four weeks (Q4W) into an expansion cohort in patients with TNBC who have received one to four prior treatment lines, including at least one prior topo-1 ADC.”

Source: [Mersana Therapeutics initial clinical data announcement (2025)](https://www.globenewswire.com/news-release/2025/01/10/3007493/0/en/Mersana-Therapeutics-Announces-Positive-Initial-Clinical-Data-from-Phase-1-Clinical-Trial-of-Emiltatug-Ledadotin-XMT-1660-Initiation-of-Expansion-in-Triple-Negative-Breast-Cancer.html)

> “All 4 pts with high B7-H4 expression treated at the initial EXP dose of 67.4mg/m2 Q4W had tumor reductions and were on treatment with durations of ≥16 weeks as of data cutoff.”

Source: [Hamilton et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009)

<a id="topic-2.1.2.10.1-5"></a>

###### Second expansion dose: split-dose lead-in followed by 80 mg/m2 every 4 weeks

> “The second dose expansion cohort is the “Dose B” cohort, in which patients are receiving 80 mg/m2 of Emi-Le Q4W following a loading dose of 44.5 mg/m2 of Emi-Le on days 1 and 8 of the first four-week cycle.”

Source: [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

> “The expansion phase, which is enrolling patients with TNBC and ACC-I, evaluates 67.4 mg/m² every 4 weeks (Q4W), a 44.5-mg/m² split-dose lead-in followed by 80 mg/m² Q4W, and 80 mg/m² Q4W.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.10.1-6"></a>

###### Dose selected for EMBLEM-1: 80 mg/m2 every 4 weeks, capped at 160 mg

> “We landed on 80 mg/m2 monthly as the preferred dose”
> “The dosing regimen is emiltatug ledadotin 80 mg/m² (capped at 160 mg) Q4W, with ORR as the primary end point and DOR, DCR, PFS, overall survival, and safety as secondary end points.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.10.1-7"></a>

###### Dose modification guidance and dosing in organ impairment

No evidence found.

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Route and schedule

> “Emi-Le will be administered through a vein in your arm or port catheter (intravenously)”
> “Single arm Emi-Le alone (monotherapy)”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

> “Pts with ACC received Emi-Le at doses of 57.4–89 mg/m2 IV per Q3W or Q4W cycle.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-2.1.2.10.2-2"></a>

###### Pretreatment requirements: brain imaging and tumor tissue

> “Tumor tissue, either archival or from a fresh tumor biopsy, available for testing or be willing to undergo a minimally invasive tumor biopsy to obtain tumor tissue for local testing, if not medically contraindicated, prior to Cycle 1 Day 1”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.1.2.10.2-3"></a>

###### Infusion duration, premedication, and preparation

No evidence found.

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Summary: access during development

Emiltatug ledadotin is available only within the NCT05377996 phase 1/2 trial, which the registry lists as recruiting, with an estimated enrollment of 360 participants aged 18 years or older. The registry record indicates that expanded access is not available. No commercial distribution model, specialty pharmacy arrangement, or site-of-care restriction has been described.

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.1.2.11-2"></a>

###### Expanded access program

No evidence found.

<a id="topic-2.1.2.11-3"></a>

###### Distribution channel and specialty pharmacy arrangements

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Renal-protective medications for proteinuria

> “After a protocol amendment introduced an updated monitoring and management plan, including renal-protective medications, proteinuria-related dose reductions decreased from 38.9% to 20% and delays from 50.0% to 6.7% among patients with ACC.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-2.1.2.12-2"></a>

###### Combination with immune checkpoint inhibitors: preclinical rationale

> “Moreover, the combination of XMT-1660 and an immune checkpoint inhibitor may be beneficial to preclude a tumor's evasion of therapy by switching from expression of one antigen to the other. Particularly in this setting, the use of an antibody that does not block the immune-suppressive function of B7-H4 (Fig. 2A) may reduce the likelihood of exacerbating immune-related toxicity induced by the checkpoint inhibitor.”

Source: [Toader et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10477829/)

<a id="topic-2.1.2.12-3"></a>

###### Clinical combination regimens

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Emiltatug Ledadotin on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Summary: comparison with other investigational agents in ACC and other B7-H4-directed ADCs

No systemic therapy is approved for recurrent or metastatic ACC, so no approved comparator exists. Emiltatug ledadotin is the only B7-H4-directed ADC identified with an FDA Breakthrough Therapy designation in ACC and a sponsor-led phase 2 trial in ACC (EMBLEM-1). In the ASCO 2026 abstract, the objective response rate was 40% (10 of 25 evaluable participants with ACC); the oral presentation reported 35.6% in 45 evaluable participants with ACC and 46.9% in 32 evaluable participants with aggressive ACC. A patient foundation described historical response rates in ACC trials as rarely above 15%. Other B7-H4-directed ADCs use topoisomerase I inhibitor payloads and have been developed mainly in gynecologic and breast cancers. Puxitatug samrotecan (AZD8205) produced 90% complete responses in two ACC-I patient-derived xenograft models and is in an investigator-sponsored phase 2 trial in ACC; in its first-in-human study (46 participants, no ACC cohort), grade 3 or higher neutropenia occurred in 37.0%. Mocertatug rezetecan (GSK5733584) is entering phase 3 trials in ovarian and endometrial cancers, and its grade 3 or higher adverse events were described as predominantly hematologic. Felmetatug vedotin (SGN-B7H4V), whose phase 1 trial listed ACC among its conditions, was terminated. In ACC, the reported safety profile of emiltatug ledadotin is dominated by proteinuria and transient AST increase, with neutropenia in 2.2% of all participants. Non-ADC investigational agents in ACC include the oral MYB mRNA degrader REM-422 (3 partial responses in 7 biomarker-positive participants at the recommended phase 2 dose), the MDM2 inhibitor alrizomadlin, and the gamma-secretase inhibitor AL101. No head-to-head or indirect comparisons were identified.

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [ACCRF (2025)](https://accrf.org/new-b7-h4-adc/); [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm); [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm); [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/); [Meric-Bernstam et al. (2024)](https://www.annalsofoncology.org/article/S0923-7534(24)02192-6/fulltext); [GSK BEHOLD-1 data announcement (2026)](https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-b7-h4-targeted-adc-in-gynaecological-cancers/); [ClinicalTrials.gov NCT05194072](https://clinicaltrials.gov/study/NCT05194072); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [Ferrarotto et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6009)

<a id="topic-2.1.2.14-2"></a>

###### Investigational agents in ACC named by the sponsor

> “Several agents are in development for ACC, though progress has been limited. Investigator-sponsored Phase 2 trials in ACC include studies of the B7-H4–targeting ADC puxitatug samrotecan (AZD8205), the TROP-2-targeting ADC sacituzumab govitecan, and the Nectin-4-targeting ADC enfortumab vedotin. Additional agents in early-phase clinical evaluation or recently completed studies in ACC include Remix Therapeutics’ MYB mRNA degrader REM-422, Ascentage’s MDM2 inhibitor alrizomadlin, and the gamma-secretase inhibitor AL101 (osugacestat), which has been studied in ACC patients with activating NOTCH mutations.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.1.2.14-3"></a>

###### Emiltatug ledadotin in ACC: response rates reported at ASCO 2026

> “Among 25 evaluable (≥1 post-baseline scan) pts with ACC, objective response rate was 40% (9/25 confirmed, 1/25 unconfirmed ongoing and on treatment) and disease control rate was 76% (19/25).”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

> “Objective response rate (ORR) was 35.6%, including one complete response.”
> “Consistent tumor shrinkage, with an ORR of 46.9%, DCR of 81.3% and median PFS of 7.8 months.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-2.1.2.14-4"></a>

###### Historical response rates in ACC clinical trials

> “Historically, clinical trials in ACC have been challenging, rarely leading to responses (at least 30% tumor shrinkage) in more than 15% of patients.”

Source: [ACCRF (2025)](https://accrf.org/new-b7-h4-adc/)

<a id="topic-2.1.2.14-5"></a>

###### B7-H4-directed ADCs in clinical development: payload comparison

> “Multiple investigational B7-H4 ADCs are in first-in-human clinical trials, including GSK5733584 (GSK plc, licensed from Hansoh Pharmaceutical Group Company Limited), puxitatug samrotecan (AstraZeneca plc), BG-C9074 (BeiGene Ltd., licensed from Duality Biologics) and LNCB74 (NextCure Inc., being co-developed with LigaChem Biosciences), with additional B7-H4 ADCs potentially in preclinical development.”
> “Among the B7-H4 ADCs currently being investigated in active clinical trials, LNCB74 is the only product candidate with an auristatin (MMAE) payload; the other B7-H4-targeting ADCs in clinical investigation carry topo-1 payloads, and none of the sponsors of the trials of these product candidates have reported observing clinical activity in patients who were previously treated with another topo-1 ADC.”

Source: [Mersana Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025009246/mrsn-20241231.htm)

<a id="topic-2.1.2.14-6"></a>

###### Puxitatug samrotecan (AZD8205): preclinical activity in ACC models

> “A single dose of AZD8205 significantly inhibited tumor growth and led to regression in 100% (n=30) of ACCX9 and ACCX11 tumors by day 60.”

Source: [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)

<a id="topic-2.1.2.14-7"></a>

###### Puxitatug samrotecan (AZD8205): first-in-human safety and activity in other solid tumors

> “AZD8205 is a novel B7-H4–directed topoisomerase I inhibitor (Top1i) ADC with favorable preclinical antitumor activity in patient-derived xenograft models with an acceptable toxicity profile.”
> “Any grade treatment-emergent adverse events (TEAEs) occurred in 97.8% of pts, most commonly nausea (58.7%), neutropenia (56.5%), and anemia (50.0%). Grade ≥3 TEAEs occurred in 82.6% of pts, most commonly neutropenia (37.0%) and anemia (30.4%).”
> “Of the 43 pts treated at doses ≥1.6 mg/kg, 9 pts with ovarian, breast or endometrial cancer had a confirmed partial response (20.9%).”

Source: [Meric-Bernstam et al. (2024)](https://www.annalsofoncology.org/article/S0923-7534(24)02192-6/fulltext)

<a id="topic-2.1.2.14-8"></a>

###### Mocertatug rezetecan (GSK5733584): phase 1 results and phase 3 plans in gynecologic cancers

> “Mo-Rez is a novel investigational B7-H4-targeted antibody-drug conjugate designed to optimise efficacy and tolerability. It is composed of a fully human anti-B7-H4 monoclonal antibody covalently linked to a topoisomerase inhibitor payload and has a drug-to-antibody ratio (DAR) of 6.”
> “Grade ≥3 TRAEs occurred in 64% and 54% patients in PROC and EC, respectively, and were predominantly haematologic, as expected for treatments in this class.”
> “Mo-Rez will advance to five pivotal global phase III trials in 2026, starting with PROC (BEHOLD-Ovarian01 / NCT07286266) and 2L EC (BEHOLD-Endometrial01 / NCT07286331).”

Source: [GSK BEHOLD-1 data announcement (2026)](https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-b7-h4-targeted-adc-in-gynaecological-cancers/)

<a id="topic-2.1.2.14-9"></a>

###### Felmetatug vedotin (SGN-B7H4V): terminated phase 1 trial that included ACC

| Field | Quoted record |
| --- | --- |
| Official title | “A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors” |
| Condition | “Adenoid Cystic Carcinoma” |
| Reason stopped | “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns” |

Source: [ClinicalTrials.gov NCT05194072](https://clinicaltrials.gov/study/NCT05194072)

<a id="topic-2.1.2.14-10"></a>

###### REM-422 (MYB mRNA degrader): phase 1 activity in recurrent or metastatic ACC

> “REM-422 is a first-in-class, potent, selective, oral small molecule mRNA degrader of MYB.”
> “The most common treatment-related adverse events at the RP2D included epistaxis (60%), fatigue (60%) and anemia (40%), all of which were grade 1 or 2.”
> “At the RP2D of 24 mg, 3 PRs were observed among 7 biomarker positive pts (ORR 42%).”

Source: [Ferrarotto et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6009)

<a id="topic-2.1.2.14-11"></a>

###### Head-to-head or indirect treatment comparisons

No evidence found.

<a id="topic-2.1.2.14-12"></a>

###### Puxitatug samrotecan (AZD8205): antibody, linker, payload, and drug-to-antibody ratio

> “Here, we describe the development of AZD8205, a novel B7-H4 directed ADC currently being evaluated in a first-in-human, phase 1 study (NCT05123482) and the first ADC to make use of the novel TOP1i linker–payload AZ14170133 (AZ’0133).”
> “The TOP1i AZ14170132 (AZ’0132; AstraZeneca) was covalently bound to native cysteines in antibody INT016 through a Val-Ala (VA) or Gly-Gly-Phe-Gly (GGFG) peptide linker with or without a PEG8 spacer, resulting in four distinct INT016-based ADCs with an approximate drug-to-antibody ratio (DAR) of 8.”
> “Ex vivo serum stability experiments indicated that the INT016-ADCs containing the PEG8 spacer (INT016-AZ’0133 and INT016-SG4057) were strikingly more stable (23.5% and 29% drug loss, respectively, after 15 days) than those lacking PEG (INT016-SG4010 and INT016-SG4052; approximately 68% drug loss after 15 days; Fig. 2C; Supplementary Fig. S7).”
> “Together, these results indicate that INT016-AZ’0133 (henceforth referred to as AZD8205) is likely to provide the widest therapeutic window among the ADCs we evaluated.”

Source: [Kinneer et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36355054/)

Additional sources: [Ho et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.3089); [ClinicalTrials.gov NCT05123482](https://clinicaltrials.gov/study/NCT05123482); [ADC Review (2025)](https://www.adcreview.com/business-economics/pfizer-discontinues-development-of-felmetatug-vedotin/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Summary: definition, molecular etiology, and the aggressive subgroup

Adenoid cystic carcinoma (ACC) is a malignancy of secretory glands that arises most often in the major and minor salivary glands of the head and neck, and less often in the tracheobronchial tree, breast, lacrimal glands, and other sites. It accounts for approximately 1% of head and neck malignancies. Tumors are biphasic (ductal and myoepithelial cells) and grow in cribriform, tubular, and solid patterns, often mixed within a single tumor. No lifestyle risk factors such as smoking or alcohol use have been linked to ACC.

The t(6;9) translocation producing the MYB-NFIB fusion is the hallmark genetic event. The reported frequency varies by detection method (28% of primary tumors by RT-PCR in one series of 123 salivary cancers; 40% to 70% by FISH), while MYB RNA expression is detected in 80% to 90% of tumors regardless of fusion status. Activating NOTCH pathway alterations, most often in NOTCH1, occur in a subset of tumors; in a genomic analysis of 1,045 ACCs, NOTCH1 alterations were present in 26.3% of recurrent or metastatic tumors and 8.5% of primary tumors.

Proteogenomic profiling of 54 tumors at MD Anderson Cancer Center defined two molecular subtypes: ACC-I (20 of 54, 37%), with MYC upregulation, enrichment of NOTCH-activating mutations, enrichment for solid histology, and median overall survival of 3.44 years; and ACC-II (34 of 54, 63%), with TP63 upregulation, predominantly cribriform and tubular histology, and median overall survival of 23.2 years. MYC and p63 immunohistochemistry reproduced this classification. Solid histology and high-grade transformation (a rare progression with nuclear enlargement and irregularity, higher mitotic counts, and loss of the biphasic ductal-myoepithelial differentiation) define the aggressive ACC population addressed in this report. Day One Biopharmaceuticals reports that up to 40% of patients have this aggressive form.

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/); [Persson et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2773970/); [Mitani et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5862426/); [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/); [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/); [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/); [Seethala et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18059225/); [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.1-2"></a>

###### Definition: a secretory gland malignancy arising mainly in the salivary glands

> “Adenoid cystic carcinoma (ACC) is a rare malignancy arising from the secretory glands, most commonly seen involving the salivary glands. It accounts for approximately 1% of all malignancies of the head and neck region.”
> “Unlike other carcinomas of the head and neck region like squamous and basal cell carcinoma, smoking and the use of alcohol have not been linked as potential risk factors for the development of ACC.”
> “Three distinct histological patterns are associated with ACC: tubular, cribriform, and solid, which are seen in varying degrees, often mixed, with the cribriform subtype being the most common.”
> “In the solid subtype, basaloid cells are arranged solid sheets, often having prominent mitotic activity and central necrosis.”

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)

> “Adenoid cystic carcinoma (AdCC) is a rare malignancy originating from secretory glands with yet unknown aetiology and accounts for approximately 1% of malignant head and neck tumours”

Source: [Zupancic et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10000643/)

> “Adenoid cystic carcinoma (ACC) is a rare malignancy arising in salivary glands and other sites, characterized by high rates of relapse and distant spread.”

Source: [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/)

<a id="topic-2.2.1.1-3"></a>

###### Etiology: MYB-NFIB fusion from the t(6;9) translocation

> “We show that the t(6;9)(q22–23;p23–24) translocation in adenoid cystic carcinomas (ACC) of the breast and head and neck consistently results in fusions encoding chimeric transcripts predominantly consisting of MYB exon 14 linked to the last coding exon(s) of NFIB.”
> “Our data indicate that the MYB-NFIB fusion is a hallmark of ACC and that deregulation of the expression of MYB and its target genes is a key oncogenic event in the pathogenesis of ACC.”

Source: [Persson et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2773970/)

> “The MYB-NFIB fusion was detected in 28% primary and 35% metastatic ACCs, but not in any of the non-ACC salivary carcinomas analyzed.”
> “Notably, MYB was overexpressed in the vast majority of the ACCs, although MYB expression was significantly higher in tumors carrying the MYB-NFIB fusion.”

Source: [Mitani et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5862426/)

> “Evidence for this fusion transcript is considered diagnostic of ACC. However, by fluorescence in situ hybridization (FISH), a commonly employed technique in clinical practice, this fusion is present in only 40 to 70% of cases”
> “On the other hand, persistent MYB RNA expression has been noted in 80 to 90% of ACC regardless of translocation status”

Source: [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/)

<a id="topic-2.2.1.1-4"></a>

###### Etiology: low mutational burden with chromatin regulator and NOTCH pathway alterations

> “These analyses revealed a low exonic somatic mutation rate (0.31 non-silent events/megabase) and wide mutational diversity.”
> “Interestingly, mutations selectively involved chromatin state regulators, such as SMARCA2, CREBBP, and KDM6A, suggesting aberrant epigenetic regulation in ACC oncogenesis.”

Source: [Ho et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3708595/)

> “An integrated genomic analysis of 1,045 ACCs (177 primary, 868 R/M) was performed to identify alterations associated with advanced and metastatic tumors.”

Source: [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/)

> “NOTCH1 mutations define a distinct disease phenotype characterized by solid histology, liver and bone metastasis, poor prognosis, and potential responsiveness to Notch1 inhibitors.”

Source: [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/)

> “Genotypically, the aggressive form of ACC is enriched for NOTCH‐activating mutations, particularly in NOTCH1 which are present in approximately 25% of cases and are significantly associated with shorter OS, higher likelihood of solid histology, higher rate of bone and liver metastases, and shorter relapse‐free survival”

Source: [Hoff et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11872804/)

<a id="topic-2.2.1.1-5"></a>

###### Molecular subtypes: ACC-I and ACC-II from proteogenomic profiling

> “Both unbiased RNA-seq and RPPA analysis revealed two molecular subtypes; ACC-I (37%) and ACC-II (63%).”
> “ACC-I had strong upregulation of MYC, MYC target genes, and mRNA splicing, enrichment of NOTCH activating mutations and dramatically worse prognosis.”
> “ACC-II exhibited upregulation of TP63 and receptor tyrosine kinases (AXL, MET, EGFR), and less aggressive clinical course.”
> “Our data suggests a model in which ACC-I is driven by MYC signaling through either NOTCH mutations or direct amplification, which in turn suppress P63 signaling observed in ACC-II producing unique therapeutic vulnerabilities for each subtype.”
> “As MYB/MYBL1-NFIB fusion are hallmark genetic events of ACC, we assessed if these fusions correlated to clustering.”
> “there was no difference in MYB/MYBL1-NFIB fusion events between ACC-I (65%, 13/20) and ACC-II (64%, 22/34)”

Source: [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)

> “Recent studies have identified two molecular subtypes based on transcriptomic profiling and MYC/TP63 expression (ACC I: MYC-high/TP63-low; ACC II: MYC-low/TP63-high) with potential prognostic significance.”
> “ACC I tumors are characterized by enhanced proliferative signaling, loss of myoepithelial differentiation, and aggressive clinical behavior, whereas ACC II tumors retain features of myoepithelial lineage differentiation and demonstrate more favorable outcomes.”

Source: [Rao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13162811/)

> “Recent molecular profiling efforts have identified two important subtypes: the more aggressive ACC-I is characterized by Notch pathway alterations and MYC amplification whereas ACC-II demonstrates a more indolent phenotype and TP63 overexpression.”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.1-6"></a>

###### Solid histology: loss of myoepithelial cells and association with ACC-I

> “Usually, loss of myoepithelial cells within a tumor is associated with emergence of a solid epithelial form and aggressive behavior, although solid subtype may be composed of myoepithelial cells”
> “Cluster I (ACC-I) (20 of 54; [37%]) was enriched for tumors with any solid component”
> “In contrast, samples in cluster II (ACC-II, 34 of 54; [63%]) contained more tumors with cribriform and tubular histology”

Source: [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)

> “Although tubular and cribriform patterns predominate myoepithelial cells, S histology is typically characterized by epithelial cell predominance”
> “ACC‐I is characterized by NOTCH pathway activation and MYC overexpression, predominantly represented by S tumors, and usually have an aggressive behavior with a median OS of 3.44 years.”

Source: [Siqueira et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12419983/)

<a id="topic-2.2.1.1-7"></a>

###### High-grade transformation: definition

> “High-grade transformation of adenoid cystic carcinoma (ACC) (previously referred to as dedifferentiation) is a rare phenomenon that does not fit into the traditional ACC grading schemes.”
> “Histologically, ACC with high-grade transformation was distinguished from conventional ACC by nuclear enlargement and irregularity, higher mitotic counts, and the loss of the biphasic ductal-myoepithelial differentiation.”
> “The most common morphologies for the high-grade component were poorly differentiated cribriform adenocarcinoma and solid undifferentiated carcinoma.”

Source: [Seethala et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18059225/)

> “Chromosomal gains were mostly confined to the areas of high-grade transformation while losses were seen only in the conventional areas.”
> “Our findings implicate C-MYC amplification in this progression, although the role of HER2/neu is still unclear.”

Source: [Seethala et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21204718/)

> “Notably, the solid subtype was the most prevalent pattern within HGT, accounting for 69.6% of cases.”
> “The findings support classifying HGT in ACC as Grade 4, reflecting its severity.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.1-8"></a>

###### Aggressive ACC: share of patients as described by the manufacturer

> “Up to 40% of patients have an aggressive form of ACC characterized by solid/basaloid or high-grade transformation histology and poor prognosis with median progression-free survival (PFS) of 2–3 months and median overall survival of approximately 3 years.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.1-9"></a>

###### Definition of ACC-I: MYC upregulation, NOTCH1 mutations, and 37% of cases

> “However, prior studies have demonstrated that NOTCH1 alterations are associated with worse outcomes, associated with more aggressive and widespread ACC (19, 20). Further, NOTCH1 mutations frequently characterize ACC-I, a subgroup of ACC tumors harboring upregulation of MYC, along with MYC target genes and mRNA splicing pathways comprising 37% of all cases linked with poor outcomes. ACC-II is characterized by increased expression of receptor kinases and TP63, often aligned with a more indolent pattern of disease growth.”
> “Adenoid cystic carcinoma (ACC) is a rare malignancy of the salivary glands and other glandular tissue accounting for 10% to 20% of all salivary gland neoplasms (1–3).”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.1-10"></a>

###### Etiology: absence of established risk factors and age at presentation

> “The tumor occurs in all age groups with a high frequency in middle-aged and older patients”
> “the 5th and 6th decades being most commonly affected”
> “There are no distinct risk factors, and smoking is not known to affect the incidence”
> “AdCC is a relentlessly growing tumor characterized by perineural invasion and multiple local recurrences.”

Source: [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)

<a id="topic-2.2.1.1-11"></a>

###### High-grade transformation: definition as an abrupt change in morphology

> “The conventional LG and HG areas are usually clearly demarcated, although a transitional zone may be present in some cases.”
> “The HG component is composed of solid nests of anaplastic cells with large vesicular pleomorphic nuclei, prominent nucleoli, and abundant cytoplasm. Frequent mitoses and extensive necrosis may be present. The Ki-67 labeling index is consistently higher in the HG component.”
> “The histologic hallmarks of HGT in AdCC include necrosis, high mitotic rate, and loss of the biphasic ductal-myoepithelial differentiation.”
> “AdCCs with both tubular and cribriform patterns generally have a better prognosis than those with solid pattern. The presence and extent of the solid pattern (currently with a cutoff of 30%) portend an accelerated and worse clinical course.”

Source: [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/)

Additional sources: [Skálová et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9018948/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Adenoid cystic carcinoma with solid histology or high-grade transformation

<a id="topic-2.2.1.2.1-1"></a>

###### Summary: incidence of ACC and of the aggressive subgroup

Population-level incidence data are reported for ACC overall, not for the solid or high-grade transformation subgroup. Reported incidence of ACC is 3 to 4.5 per million, and approximately 1,200 to 1,300 new cases are diagnosed annually in the United States. In the Surveillance, Epidemiology, and End Results (SEER) program, 3,026 head and neck ACC cases were recorded between 1973 and 2007 (mean age at diagnosis 57.4 years), with a decline in incidence over that period. ACC represents 10% to 25% of malignant salivary gland tumors.

No registry reports incidence of aggressive ACC directly. Estimates of the aggressive share come from institutional series: ACC-I accounted for 20 of 54 tumors (37%) in a proteogenomic cohort; high-grade transformation was identified in 23 of 412 ACC cases (5.6%) at a single center in China; and solid-type histology was present in 27.5% of 58 cases at a Japanese institution. Day One Biopharmaceuticals reports that up to 40% of patients have aggressive ACC.

Source: [Rahouma et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11476411/); [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/); [Day One Biopharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066926/dawn-ex99_3.htm); [Ellington et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22294420/); [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/); [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/); [Ishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330995/); [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.2.1-2"></a>

###### Incidence of ACC overall: rate per million

> “ACC is a rare malignant tumor with a reported incidence of 3–4.5 per million”
> “It arises mainly from minor and major salivary glands, representing 10–25% of malignant tumors of salivary glands”
> “A total of 5150 patients were included (4.2% from the Midwest, 17.2% from the Northeast, 22.5% from the South, and 56.1% from the West regions).”

Source: [Rahouma et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11476411/)

> “It is diagnosed in roughly four per one million people annually, and does not discriminate by ethnicity or lifestyle factors.”

Source: [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence of ACC overall: annual cases in the United States

> “Here, we evaluate the comparative genomic landscapes of primary versus R/M ACC in 1045 sequenced cases, a cohort size that approximates the annual incidence of ACC in the United States (approximately 1200 per year).”

Source: [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/)

> “Annual U.S. incidence of ~1,300 patients, including: ACC-1 subtype Clinically aggressive non-ACC-1”

Source: [Day One Biopharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066926/dawn-ex99_3.htm)

<a id="topic-2.2.1.2.1-4"></a>

###### Incidence trends and age at diagnosis: SEER 1973 to 2007

> “The authors identified 3026 patients with ACCHN. The mean age at diagnosis among those cases was 57.4 years (range, 11-99 years). Analyses of incidence data demonstrated a decline in ACCHN rates between 1973 and 2007, noted across all sexes and races with no detectable inflexion points.”

Source: [Ellington et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22294420/)

> “AdCC can occur at all ages but is most common later in life (Fifth to Sixth decade)”

Source: [Zupancic et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10000643/)

<a id="topic-2.2.1.2.1-5"></a>

###### Frequency of the aggressive subgroup: ACC-I, solid histology, and high-grade transformation

> “Cluster I (ACC-I) (20 of 54; [37%]) was enriched for tumors with any solid component”

Source: [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)

> “Five independent cohorts from two publications comprising 247 patients (90 ACC I, 157 ACC II) were included.”

Source: [Rao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13162811/)

> “Histology was cribriform/tubular type (C-T type) in 62.0% and solid type in 27.5%.”

Source: [Ishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330995/)

> “A 1:1 match comparison between 23 HGT patients and non-HGT counterparts was extracted from 412 ACC cases, focusing on dissecting distinctive clinicopathological features and prognostic outcomes.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

> “Up to 40% of patients have an aggressive form of ACC characterized by solid/basaloid or high-grade transformation histology”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-2.2.1.2.1-6"></a>

###### Frequency of high-grade transformation in a consecutive single-center ACC series

> “A total of 412 ACCs diagnosed pathologically at Beijing Tongren Hospital between June 2008 and December 2019 were identified, including 23 HGT cases and 389 non-HGT cases.”
> “Our study further emphasizes its rarity, as only 23 (5.6%) out of 412 head and neck ACCs exhibited HGT.”
> “In ACC, HGT remains an uncommon finding. Less than a hundred cases have been reported in the English literature”
> “with the majority being case reports.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.2.1-7"></a>

###### Published cases of high-grade transformation in adenoid cystic carcinoma

> “Since the original description of 3 cases of HGT/dedifferentiation in AdCCs (both de novo and in recurrences) by Cheuk et al”
> “> 50 cases have now been published.”

Source: [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/)

<a id="topic-2.2.1.2.1-8"></a>

###### Annual cases of ACC diagnosed in the United States

> “Each year around 1,600 cases of ACC are diagnosed within the United States (4), typically presenting with locoregional disease.”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.2.1-9"></a>

###### Population-based incidence of ACC and share of salivary gland cancers

> “A large Danish population-based study estimates that AdCC accounts for 27.9% of the overall incidence of salivary gland cancers (SGCs) (11/1,000,000/year), corresponding to an annual incidence of 3/1,000,000/year”
> “In Nova Scotia, the annual incidence raises to 4.5/1,000,000 cases”
> “AdCC is the most common cancer in MSGs, where the proportion of AdCC ranges from 32% to 71%.”

Source: [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)

Additional sources: [Boyle et al. (2020)](https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e13600)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Adenoid cystic carcinoma with solid histology or high-grade transformation

<a id="topic-2.2.1.2.2-1"></a>

###### Summary: prevalence of ACC and of the aggressive subgroup

No published source reports the prevalence of ACC with solid histology or high-grade transformation. For ACC overall, Servier reports that more than 200,000 people have ACC worldwide. For all salivary gland cancers, the estimated global 1-year prevalence is about 42,000 cases (GLOBOCAN 2022). A 2020 ASCO abstract on the epidemiology of ACC in the United States could not be retrieved for quotation. Because survival in aggressive ACC is shorter than in ACC-II (median overall survival 3.44 versus 23.2 years in a proteogenomic cohort of 54 participants), the aggressive subgroup is expected to represent a smaller share of prevalent cases than of incident cases.

Source: [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC); [Singer et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12703571/); [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence of ACC overall: global estimate

> “Globally, more than 200,000 people have ACC.”

Source: [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC)

<a id="topic-2.2.1.2.2-3"></a>

###### Prevalence of salivary gland cancers overall: GLOBOCAN 2022

> “It is a rare condition, with an estimated number of cases (1‐year prevalence) of about 42 000 worldwide”

Source: [Singer et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12703571/)

Additional sources: [Boyle et al. (2020)](https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e13600)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Summary: survival in aggressive ACC compared with cribriform and tubular ACC

ACC overall has an indolent early course with continued late recurrence and mortality. In SEER (3,026 head and neck cases), 5-, 10-, and 15-year survival was 90.3%, 79.9%, and 69.2%. In institutional series, 5-year survival of 74% to 85% declines to 50% to 64% at 10 years and 20% at 25 years, and more than 50% of tumors recur or metastasize. Mortality continues beyond 20 years: a review of long-followed series reports 5-, 10-, and 20-year survival of 68%, 52%, and 28% in one cohort of 105 participants, 40% of participants alive at 20 years in a United Kingdom series in which the actuarial primary site recurrence rate at 30 years was 100%, and attributes the low long-term survival to failure to control distant disease. In a contemporary cohort of 161 participants at one center, 86% of whom had recurrent disease, median overall survival from diagnosis was 13.9 years (95% CI 9.39 to 17.8), and NOTCH1 status was associated with survival from diagnosis (P = 0.040) and from recurrence (P = 0.007).

Solid histology and ACC-I status are associated with shorter survival. In the original Szanto grading series (79 participants), 15-year survival was 39%, 26%, and 5% for grades I, II, and III (predominantly solid), and grade III tumors caused death within 4 years. In a proteogenomic cohort of 54 participants, median overall survival was 3.44 years for ACC-I and 23.2 years for ACC-II; a 2026 meta-analysis of 247 participants from 5 cohorts found a pooled hazard ratio for death of 3.88 (95% CI 2.55 to 5.90) for ACC-I versus ACC-II. NOTCH1-mutant tumors had median overall survival of 30 months versus 122 months for wild-type tumors. High-grade transformation carries the poorest reported outcomes. In a 9-participant series, 5 died within 5 years and median overall survival was 12 months. In a 1:1 matched series of 23 transformed and 23 non-transformed cases drawn from 412 ACCs, mortality was 47.8% (11 of 23) versus 8.7% (2 of 23), 3-year mortality was 34.8% (8 of 23) versus 4.3% (1 of 23), average survival was 35.9 versus 55.9 months, and median progression-free survival was 18.0 versus 37.0 months, although median follow-up was shorter in the transformed group (29.0 versus 39.0 months); distant metastasis occurred in 78.3% (18 of 23), the lung was the first site in 83.3% (15 of 18), and median survival after metastasis was 8.0 versus 16.5 months. A pathology review describes salivary gland carcinomas with high-grade transformation as more aggressive than conventional carcinomas, with higher local recurrence, a high propensity for cervical lymph node metastasis, and poorer prognosis. After distant metastasis, solid-type ACC had shorter survival and more frequent multiorgan metastases (17 of 28, 61%) than non-solid ACC, and metastases outside the lung were associated with shorter survival (median 11.04 versus 44.52 months in one series of 51 participants).

Source: [Ellington et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22294420/); [Zupancic et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10000643/); [Ishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330995/); [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/); [Szanto et al. (1984)](https://pubmed.ncbi.nlm.nih.gov/6088017/); [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/); [Rao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13162811/); [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/); [Seethala et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18059225/); [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/); [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/); [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005); [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/); [van Weert et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27775851/); [Bölek et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12481798/)

<a id="topic-2.2.1.3-2"></a>

###### ACC overall: long-term survival in SEER and institutional cohorts

> “The overall 5-year, 10-year, and 15-year survival outcomes for ACCHN patients were 90.3%, 79.9%, and 69.2%, respectively.”

Source: [Ellington et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22294420/)

> “Median overall survival was 11.0 (95% CI: 9.2-NR years), 14.3 (95% CI: 12.4–16.4 years), 11.3 (95% CI: 9.7–14.8 years), and 12.0 (95% CI: 11.3–13.0 years) for Midwest, Northeast, South, and West regions, respectively.”

Source: [Rahouma et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11476411/)

> “Due to its slow growth, the disease often runs an indolent course, with 5-year survival rates of 80–85%, but contrary to other head and neck cancers, these promising numbers decline when following 10- and 15-year survival rates, which are 50–60% and 30–35%, respectively”

Source: [Zupancic et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10000643/)

> “Five-year, 10-year, 15-year, 20-year, and 25-year OS rates were 74.0, 63.7, 41.0, 27.3, and 20.0%, respectively.”

Source: [Ishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330995/)

<a id="topic-2.2.1.3-3"></a>

###### ACC overall: recurrence and distant metastasis over time

> “More than 50% of ACCs recur or develop distant metastases over time. Relapsed tumors are generally incurable because no systemic agents to date have been found to be effective. Therefore, overall prognosis has remained poor, with long-term overall survival (OS) rates of 23%–40%”

Source: [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/)

> “AdCC is usually treated with surgery upfront, often followed by postoperative radiotherapy, but despite an aggressive therapy regimen late (>5 years after primary treatment), local relapse (15–85%) and distant metastases (25–55%) are common”

Source: [Zupancic et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10000643/)

> “ACC usually is an aggressive, although slowly growing, cancer with a long-term poor prognosis. Most patients (80–90%) with ACC of the head and neck die within 10–15 years after diagnosis.”

Source: [Persson et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2773970/)

<a id="topic-2.2.1.3-4"></a>

###### Solid histology versus cribriform and tubular histology: histologic grade and survival

> “Three histologic grades were established: Grade I, tumors with tubular and cribriform areas but without solid components; Grade II, cribriform tumors that were either pure or mixed with less than 30% of solid areas; and Grade III, tumors with a predominantly solid pattern. Cumulative survival rates at 15 years were 39%, 26%, and 5%, for Grades I, II, and III, respectively. Grade III tumors were larger, recurred frequently, and killed the patients within 4 years.”

Source: [Szanto et al. (1984)](https://pubmed.ncbi.nlm.nih.gov/6088017/)

> “The presence of any solid component in ACC is a negative prognosticator, and can histopathologically be diagnosed with a high reliability.”

Source: [van Weert et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25456010/)

> “Conducting surgery (HR: 0.19, 95% CI: 0.06–0.61, p  = 0.005) and C-T type (HR: 0.32, 95% CI: 0.11–0.93, p  = 0.036) were independent prognostic predictors of DSS.”

Source: [Ishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330995/)

<a id="topic-2.2.1.3-5"></a>

###### Molecular subtype: ACC-I versus ACC-II survival

> “Notably, the expression groups were highly prognostic, with ACC-I subjects exhibiting markedly worse OS than ACC-II; specifically, median OS was 3.44 years (95% CI=2.31–6.00) for ACC-I, and 23.2 years (95% CI= 14.0-inf.) for ACC-II (p<0.001)”

Source: [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)

> “ACC I was associated with significantly worse overall survival compared with ACC II, with a pooled HR of 3.88 (95% CI: 2.55–5.90; p < 0.001).”
> “ACC I tumors confer an approximately four-fold higher mortality risk compared with ACC II tumors.”

Source: [Rao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13162811/)

> “When pooling systemic treatment categories, ACC-I patients had worse outcomes with available therapies (HR, 3.06; 95% confidence interval, 1.65-5.68; P < 0.01), with no significant difference in overall survival between ACC-I/II based on chemotherapy or VEGFR tyrosine kinase inhibitor exposure in smaller subsets.”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.3-6"></a>

###### NOTCH1-mutant ACC: relapse-free and overall survival

> “NOTCH1 mutations define a distinct aggressive ACC subgroup with a significantly higher likelihood of solid subtype (P < .001), advanced-stage disease at diagnosis (P = .02), higher rate of liver and bone metastasis (P ≤ .02), shorter relapse-free survival (median, 13 v 34 months; P = .01), and shorter overall survival (median 30 v 122 months; P = .001) when compared with NOTCH1 wild-type tumors.”

Source: [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/)

> “Molecular findings predicted outcomes: 10-y OS: 100% MYB, 53.3% PI3K, 32.1% NOTCH1 and others, p = 0.03.”

Source: [Hanna et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32283496/)

<a id="topic-2.2.1.3-7"></a>

###### High-grade transformation: survival and mortality

> “Five of 9 patients (55.6%) died, all within 5 years with a median overall survival of 12 months.”
> “ACC-high-grade transformation is a highly aggressive salivary gland tumor with a variety of histologic patterns.”

Source: [Seethala et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18059225/)

> “HGT was associated with increased recurrence (55.0%) and distant metastasis (78.3%), leading to an average survival of 35.9 months and a 3-years mortality rate of 35.0%. Overall and progression-free survival rates were significantly decreased in the HGT group.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.3-8"></a>

###### Metastatic disease: survival by histology and metastatic site

> “Forty-two percent of the patients were diagnosed with distant metastases.”
> “Median distant metastatic survival was 13.8 months. The most frequent organ sited was the lung. Solid type ACC showed a preponderance for multiorgan metastases (17/28; 61%).”
> “Solid type ACC had a significant poorer survival after development of distant metastases.”

Source: [van Weert et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27775851/)

> “The median overall survival (OS) for the entire cohort was 29.21 months. Patients with lung metastases had significantly longer OS compared to those without (44.52 vs. 11.04 months, p  = 0.008).”

Source: [Bölek et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12481798/)

> “One hundred seventy-four patients with metastatic HNACC were enrolled and median overall survival (OS) was 45.6 months.”

Source: [Zhang et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35822446/)

<a id="topic-2.2.1.3-9"></a>

###### Aggressive ACC: progression-free and overall survival as reported by the manufacturer

> “ACC-1 is a rare and aggressive cancer that most frequently originates in the salivary glands. With no approved therapies, median PFS and median overall survival for patients with ACC-1 are reported to be 2-3 months and 2-3 years, respectively.”

Source: [Mersana Therapeutics ASCO 2025 announcement (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925055240/tm2516680d1_ex99-1.htm)

<a id="topic-2.2.1.3-10"></a>

###### Time to locoregional recurrence or metastasis after diagnosis

> “Approximately 50% to 70% of patients develop locally recurrent or metastatic disease within 5 years of diagnosis, although late recurrences more than a decade after treatment are not uncommon (1, 9–12).”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.3-11"></a>

###### Survival and recurrence in ACC series followed beyond 20 years

> “In a large European study on AdCC of the head and neck, the 10-year survival rate was 65%”
> “reported 5-, 10- and 20-year survival rates of 68%, 52% and 28%, respectively, on a series of 105 patients.”
> “reported that overall and recurrence-free survival rates at three years were 84.6% and 58.2%, respectively, while the rate of survival with recurrence was 26.4%. After 15 years, the overall survival rate was 24.5%, and the recurrence-free survival rate was 22.6%.”
> “In a UK series, 40% of AdCC patients were alive at 20 years and survival continued to drop until 30 years; the actuarial primary site recurrence rate at 30 years in that study was 100%”
> “and it was 54% in the Australian series.”
> “The low long-term survival rate of AdCC patients is uniformly linked to the failure to control distant disease. These distant metastases occur most frequently in the lung.”

Source: [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)

<a id="topic-2.2.1.3-12"></a>

###### High-grade transformation versus matched conventional ACC: mortality with follow-up duration

> “After a median follow-up of 29.0 months (range 6–108 months), the mortality rate was 47.8% (11/23), with an average survival of 35.9 months. The 3-year mortality rate was 34.8% (8/23), and the median PFS was 18.0 months (mean 25.1 months).”
> “Their median follow-up was 39.0 months (range 13–152 months), with a mortality rate of 8.7% (2/23) and an average survival time of 55.9 months. The 3-year mortality rate was 4.3% (1/23), and the median PFS was 37.0 months (mean 36.1 months).”
> “The HGT group had a median survival time of 29.0 months, a 5-year mortality rate of 34.8% (8/23), and a mean survival time of 35.8 months, consistent with the poor prognosis reported in the literature.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.3-13"></a>

###### High-grade transformation: survival after distant metastasis

> “In the HGT group, distant metastasis was 78.3% (18/23), with the lungs being the primary site in 83.3% (15/18). Post-metastasis survival averaged 9.0 months (median 8.0 months).”
> “Post-metastasis survival averaged 25.8 months (median 16.5 months), and 8.7% (2/23) had cervical lymph node metastasis at initial diagnosis.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.3-14"></a>

###### High-grade transformation across salivary gland carcinomas: recurrence and prognosis

> “Salivary gland carcinomas with HGT are more aggressive than conventional carcinomas, with a higher local recurrence rate and a poorer prognosis. They have a high propensity for cervical lymph node metastasis suggesting a need for a wider resection and neck dissection.”
> “AdCC-HGT is a biologically aggressive tumor, and hence it displays a high frequency of locoregional recurrence and metastasis to lymph nodes and distant sites.”

Source: [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/)

<a id="topic-2.2.1.3-15"></a>

###### EQ-5D value score and risk of death: time-dependent Cox proportional hazards model

| Model parameter | Value |
| --- | --- |
| Hazard ratio (95% confidence intervals), time-dependent linear Cox model | “0.118 (0.057–0.244)” |
| Standard error | “0.371” |
| P value, chi-squared comparison with a non-linear model built using penalised splines | “0.011” |

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)

<a id="topic-2.2.1.3-16"></a>

###### Non-linear relationship between EQ-5D value score and survival

> “However, there was a significant non-linear relationship between EQV and survival over time (p = 0.011; Table 3). Fig. 3 shows the modelled non-linear survival probability over time per EQV decile. A greater marginal effect on survival was seen for the difference in EQV above the median value of 0.81.”

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)

<a id="topic-2.2.1.3-17"></a>

###### Overall survival and prognostic factors in the 161-participant EQ-5D-5L cohort

> “As expected, median overall survival from diagnosis was 13.9 years (95 % confidence interval: 9.39 – 17.8)”
> “we found NOTCH1 status to be significantly associated with both survival from diagnosis (p = 0.040) and survival from recurrence (p = 0.007) in our cohort.”
> “The other parameters evaluated were location of primary site, sex, and recurrence status, with no significant associations found.”

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)

Additional sources: [Lombardi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35158286/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Summary: biology of aggressive ACC

Conventional ACC is composed of luminal ductal cells and abluminal myoepithelial cells. MYB activation, through MYB-NFIB or MYBL1-NFIB fusion or other mechanisms, is the common oncogenic event, and MYB/MYBL1 fusion rates do not differ between ACC-I (65%) and ACC-II (64%). The aggressive phenotype is associated with loss of myoepithelial differentiation, solid growth, MYC upregulation (through NOTCH activation or MYC amplification), and suppression of p63 signaling. NOTCH1 alterations are enriched in recurrent or metastatic tumors (26.3% versus 8.5% in primary tumors). High-grade transformation shows chromosomal gains confined to the transformed areas, including C-MYC gains. ACC-I tumors are immune-excluded and overexpress the immune checkpoint B7-H4, whose expression level was an independent predictor of poor survival.

Source: [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/); [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/); [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/); [Seethala et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21204718/); [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)

<a id="topic-2.2.1.4-2"></a>

###### Tumor architecture: biphasic ductal and myoepithelial cells with perineural invasion

> “Conventional ACC is a basaloid biphasic tumor with abluminal myoepithelial cells and luminal ductal cells arranged in tubular, cribriform and solid growth patterns, consistently demonstrating isomorphic, angulated, and hyperchromatic nuclei.”
> “Despite its monomorphic cytonuclear appearance, ACC stands at odds with other basaloid biphasic tumors in that it is highly infiltrative and neurotropic, requiring a wider resection and radiotherapy for disease control”

Source: [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/)

> “the loss of myoepithelial cells is associated with solid histology, aggressive clinical behavior, and poor prognosis”

Source: [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)

<a id="topic-2.2.1.4-3"></a>

###### MYB activation: loss of microRNA regulation and downstream targets

> “The minimal common part of MYB deleted as the result of fusion was exon 15 including the 3′-UTR, which contains several highly conserved target sites for miR-15a/16 and miR-150 microRNAs.”
> “We suggest that deletion of these target sites may disrupt repression of MYB leading to overexpression of MYB-NFIB transcripts and protein and to activation of critical MYB targets, including genes associated with apoptosis, cell cycle control, cell growth/angiogenesis, and cell adhesion.”

Source: [Persson et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2773970/)

<a id="topic-2.2.1.4-4"></a>

###### NOTCH-MYC axis in ACC-I

> “An association between MYC gene activation and the loss of myoepithelial cells can be empirically deduced from the high expression of the MYC gene in the solid form and the lack of expression in normal and neoplastic myoepithelial cells as observed in the ACC-I subgroup.”
> “At the genetic level, target DNA-sequencing revealed that ACC-I exhibited a higher tumor mutation burden (TMB) as compared to ACC-II (median mutations per megabase = 2.3 vs 0.7, p=0.004)”

Source: [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)

> “NOTCH1 mutations occurred predominantly (14 of 15 patients) in the negative regulatory region and Pro-Glu-Ser-Thr–rich domains, the same two hotspots seen in T-cell acute lymphoblastic leukemias, and led to pathway activation in vitro.”

Source: [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/)

> “MYC expression was 1.61-fold higher (39.8 vs. 24.7; P < 0.0001) among NOTCH1-mutant ACC-I tumors, whereas MYB/L1 fusion rates were similar among ACC-I/II.”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.4-5"></a>

###### Progression to recurrent or metastatic disease: enrichment of NOTCH and chromatin-remodeling alterations

> “Compared with primary tumors, R/M tumors were enriched for alterations in key Notch (NOTCH1, 26.3% vs. 8.5%; NOTCH2, 4.6% vs. 2.3%; NOTCH3, 5.7% vs. 2.3%; NOTCH4, 3.6% vs. 0.6%) and chromatin-remodeling (KDM6A, 15.2% vs. 3.4%; KMT2C/MLL3, 14.3% vs. 4.0%; ARID1B, 14.1% vs. 4.0%) genes.”

Source: [Ho et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763222/)

<a id="topic-2.2.1.4-6"></a>

###### High-grade transformation: progressive chromosomal alterations

> “Regions that showed the significant losses included 9q34, 4p16, 1p36.1, and 11q22.”
> “High-grade transformation in adenoid cystic carcinoma is a complex process that is reflected by several chromosomal alterations.”

Source: [Seethala et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21204718/)

> “Moreover, HGT regions typically showed reduced or absent p63 expression, along with high-grade pathomorphology.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.4-7"></a>

###### Tumor microenvironment: immune exclusion and B7-H4 overexpression in ACC-I

> “ACC-I tumors with a poor prognosis harbored a higher density of immune cells; however, spatial analysis by IMC revealed that ACC-I immune cells were significantly restricted to the stroma, characterizing an immune-excluded TME. ACC-I tumors overexpressed the immune checkpoint B7-H4, and the degree of immune exclusion was directly correlated with B7-H4 expression levels, an independent predictor of poor survival.”

Source: [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)

<a id="topic-2.2.1.4-8"></a>

###### Genomic landscape in 438 profiled tumors: fusion, mutation, and copy-number frequencies

> “MYB/L1 fusions were the most common genomic alteration observed (56.9%) across the cohort, followed by NOTCH1 (17.0%)”
> “High TMB (≥10 mutations/Mb) was infrequent, observed in only 6 (1.5%) of all ACC tumors sampled, and none were mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H).”
> “Overall, copy-number amplification (CN amp) events were infrequent but were most commonly observed for genes located on the 4q12 amplicon, including KIT (3.2%), PDGFRA (3.2%), CHIC2 (3.0%), and KDR (2.5%), which were often co-amplified.”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.4-9"></a>

###### Immune microenvironment by subtype: B7-H4 expression and immune cell fractions

> “The median cell fraction (%) of B cells in the TME was higher among ACC-II (7.1% vs. 5.8%; P < 0.01), along with greater proportions of M2 macrophages (4.8% vs. 3%, P < 0.05) and neutrophils (2.8% vs. 1.3%, P < 0.05; Fig. 2B).”
> “Expression of B7-H4, an important negative regulator of T-cell immunity, was significantly higher in ACC-I (P < 0.001).”
> “PD-L1 positivity was observed in 7 (1.9%) of all samples”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.4-10"></a>

###### Molecular changes underlying high-grade transformation: p53 and copy-number alterations

> “The pathogenesis of HGT in AdCC is not well understood, although p53 alterations may play a significant role in the evolution of this phenomenon.”
> “Using high-resolution microarray comparative genomic hybridization, Costa et al”
> “studied 6 cases of AdCC-HGT as well as 5 cases of solid AdCC. Interestingly, the authors found that AdCC-HGT carried fewer copy number changes compared with solid AdCC.”

Source: [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/)

<a id="topic-2.2.1.4-11"></a>

###### Markers associated with solid histology: NGF, EphA2, ILK, and EN1

> “Increased expression of NGF is observed in 79% of solid type AdCCs (or 68% of all studied AdCC) and may relate to its neurotropism”
> “The overexpression is significantly greater in solid AdCC than in tubular and cribriform types and correlates with microvessel density, TNM staging and perineural and vascular invasion”
> “Expression of ILK correlates strongly with solid type AdCC, advanced TNM stage and increased risk of recurrence.”
> “EN1 protein expression seems typical for solid AdCC and implies a significantly lower survival rate.”

Source: [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Summary: histologic diagnosis, grading, and molecular testing

ACC is diagnosed by biopsy with histology and immunohistochemistry, after CT or MRI to define local extent and stage. Grading is based on the solid component: the Perzin/Szanto system uses a >30% solid cutoff, the Spiro system >50%, the van Weert system the presence of any solid component, and the WHO notes a worse course when the solid component exceeds one third of the tumor. Interobserver agreement was moderate for the Perzin/Szanto (kappa 0.393) and Spiro (kappa 0.433) systems and 0.990 for the van Weert system. High-grade transformation is distinguished from solid ACC by nuclear enlargement and irregularity, higher mitotic counts, and loss of biphasic differentiation.

Molecular testing supports diagnosis and subtyping. MYB::NFIB FISH had 42.9% sensitivity and 100% specificity, and a MYB RNA in situ hybridization model had 93.2% sensitivity and 97.1% specificity in 79 cases. ACC-I and ACC-II can be assigned with MYC and p63 immunohistochemistry (AUROC 0.99). NOTCH pathway activation can be identified by genomic sequencing or NICD1 immunohistochemistry.

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/); [van Weert et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25456010/); [Morita et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7935776/); [Seethala et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18059225/); [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/); [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/); [Hoff et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11872804/)

<a id="topic-2.2.1.5-2"></a>

###### Diagnostic workup: imaging and biopsy with immunohistochemistry

> “Radiological investigations like computerized tomography (CT) and magnetic resonance imaging (MRI) are the imaging modalities of choice to help delineate the extension of the primary tumor as well as for staging purposes.”
> “A biopsy of the tumor is needed for definitive diagnosis where the characteristic histological features along with the immunohistochemical markers like smooth muscle actin, S100, vimentin, as well as for MYB and CD 117 (c-kit) confirm the diagnosis.”

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)

> “It frequently presents with unspecific symptoms, slow growth, the perineural invasion, and it is often problematic to diagnose because of the difficulty in defining its clinical differentiation and distinguishing it from benign tumours”

Source: [Zupancic et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10000643/)

<a id="topic-2.2.1.5-3"></a>

###### Histologic grading: Perzin/Szanto, Spiro, and van Weert systems

> “Two grading systems most commonly used are those described by Perzin et al./Szanto et al. and Spiro et al., respectively. They report that prognosis of ACC is poor if >30% and >50% of the tumor volume has a solid growth pattern, respectively.”
> “Inter-observer concordance for grading ACC according to Perzin et al./Szanto et al. and Spiro et al., proved to be moderate with Kappa Scores of 0.393 and 0.433, respectively. Our alternative grading system yielded inter-observer concordance with a Cohen's kappa result of 0.990.”
> “These results suggest to merely register the presence or absence of a solid tumor component since its inter-observer variability is very low, its reproducibility is high and its predictive value is comparable to the traditional grading systems used.”

Source: [van Weert et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25456010/)

> “According to the current WHO classification for salivary gland tumors, AdCC cases with a solid component constituting more than one third of the tumor may have a worse clinical course.”
> “The reproducibility of the minAmax system (kappa coefficient of 0.81) was scored as very good while those of the other three systems were scored as moderate.”

Source: [Morita et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7935776/)

<a id="topic-2.2.1.5-4"></a>

###### High-grade transformation: diagnostic criteria

> “The importance and minimal criteria for distinction from solid (grade III) ACC are not well established.”
> “Useful supportive criteria were prominent comedonecrosis and fibrocellular desmoplasia.”
> “Ki-67 and p53 labeling indices were elevated in the high-grade components, though c-kit and cyclin-D1 were not.”

Source: [Seethala et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18059225/)

> “Compared to non-HGT, the HGT cohort exhibited significantly higher rates of lymph node metastasis (39.1% vs. 8.7%; P < 0.05), perineural invasion (60.9% vs. 26.1%; P < 0.05), and increased Ki-67 proliferation index (35.0% vs. 10.0%; P < 0.05).”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.5-5"></a>

###### Molecular testing: MYB::NFIB FISH and MYB RNA in situ hybridization

> “Original scoring criteria yielded a 95.5% sensitivity (Sn), 68.6% specificity (Sp), and 83.5% accuracy. MYB::NFIB FISH yielded a 42.9% sensitivity, 100% specificity, and 60% accuracy.”
> “Optimizing for performance, simplicity, and minimal collinearity, our final model was defined as: abluminal pattern and/or % LS > 16.5%, which resulted in a 93.2% Sn, 97.1% Sp, and 94.9% accuracy for ACC diagnosis.”
> “MYB IHC was soon touted as an inexpensive practical alternative to FISH or other molecular testing. However, again, evidence to date suggest that the sensitivity and specificity are somewhat limited”

Source: [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/)

<a id="topic-2.2.1.5-6"></a>

###### Molecular subtyping: MYC and p63 immunohistochemistry

> “Furthermore, immunohistochemical staining for MYC and P63 protein levels can be used to identify ACC subtypes, enabling rapid clinical deployment to guide therapeutic decisions.”
> “To assess the clinical utility of these biomarkers, we performed IHC for both markers and found they could robustly stratify ACC tumors by subtype (AUROC = 0.99”

Source: [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)

> “Prognostic separation was consistent across RNA sequencing and immunohistochemistry-based classification methods.”
> “However, histologic grading suffers from interobserver variability and fails to fully explain the marked heterogeneity in survival observed among patients with similar clinicopathologic features”

Source: [Rao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13162811/)

<a id="topic-2.2.1.5-7"></a>

###### Molecular testing: NOTCH pathway activation

> “NOTCH pathway activation was assessed through genomic analysis for NOTCH‐activating mutations or immunohistochemistry for NOTCH1 intracellular domain (NICD1).”
> “NOTCH‐activating mutations were identified in 82% of patients, and 95% showed positive NICD1 staining.”

Source: [Hoff et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11872804/)

> “NOTCH1-mutant tumors demonstrated significantly higher levels of Notch1 pathway activation than wild-type tumors on the basis of Notch1 intracellular domain staining (P = .004).”

Source: [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/)

<a id="topic-2.2.1.5-8"></a>

###### Assignment of ACC-I and ACC-II by MYC and TP63 expression

> “High- versus low-transcriptional expression of MYC and TP63 were defined by median expression level of each gene for stratification. Samples with high MYC/low TP63 were categorized as ACC-I, whereas those with high TP63/low MYC were categorized as ACC-II”
> “Intermediate classification denotes a situation in which both genes are concurrently up or downregulated.”
> “Further, NOTCH1 mutations were observed in 46.0% versus 3.5% (P < 0.0001) of ACC-I and ACC-II cases, respectively.”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.1.5-9"></a>

###### Distinguishing high-grade transformation from solid-pattern ACC

> “It is mainly the cytomorphologic features that allow for a distinction between AdCC-HGT and the solid pattern of AdCC.”
> “Although a higher degree of nuclear atypia, a higher number of mitotic figures, and focal necrosis can be encountered in solid AdCCs, the neoplastic cells still have scanty cytoplasm and rather uniform nuclear features. In contrast, the cells of AdCC-HGT display a noticeable variation of nuclear size and shape, vesicular chromatin, increased nucleolar size, and more abundant cytoplasm.”
> “The Ki-67 index is significantly increased in the HG component compared with conventional tubular and cribriform AdCC (Fig. 3D).”

Source: [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/)

<a id="topic-2.2.1.5-10"></a>

###### Diagnostic criteria for high-grade transformation applied in a 412-case series

> “The diagnosis of HGT was established based on the criteria delineated by Seethala et al.”
> “Microscopically, HGT components were deemed 'focal' if below 10% and 'diffuse' if above 10%.”
> “In the subsequent 5th (2022) edition of the WHO classification of head and neck tumors, specific morphological descriptions distinguishing HGT from conventional salivary gland carcinomas have been incorporated. These descriptions emphasize features like cellular pleomorphism, high mitotic activity, and necrosis. All HGT cases in this study met the aforementioned diagnostic criteria (Fig. 6).”
> “the distinguishing features of HGT include significant cellular atypia, vesicular nuclei, prominent nucleoli, high mitotic activity, frequent necrosis (including comedonecrosis), desmoplastic proliferation, and calcification, along with the occasional occurrence of squamous metaplasia and micropapillary architecture”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.5-11"></a>

###### Histologic grading by proportion of solid pattern, and limits of fine needle aspiration cytology

> “Classic AdCC often shows a combination of cribriform and tubular patterns. In most studies, a solid growth pattern is associated with worse prognosis, advanced stage and development of distant metastases”
> “proposed a histologic grading scheme for AdCCs based on the degree of solid pattern. Three grades were suggested: Grade I, tumors with tubular and cribriform areas, but without solid components; Grade II, cribriform tumors that were purely or mixed with >30% of solid areas; and Grade III, tumors with a predominantly solid pattern.”
> “Fine needle aspiration cytology (FNAC) can be used for diagnostic purposes. The finding of large globules of extracellular matrix, partially surrounded by basaloid cells, suggests AdCC”
> “However, diagnosis of salivary cancers by FNAC is notoriously difficult and is often compromised by false negative evaluations”

Source: [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)

Additional sources: [Geiger et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33900808/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Local tumor symptoms: slow-growing painless mass of the head and neck

> “The prolonged asymptomatic clinical course of ACC may cause a delay in seeking medical attention.”
> “The most common presentation of ACC is a slow-growing, hard painless swelling in the head and the neck region, though pain and paresthesia are not uncommon as the tumor is notorious for perineural infiltration with the highest rates of perineural involvement seen in tumors arising from the parotid gland.”

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)

<a id="topic-2.2.1.6-2"></a>

###### Neurological symptoms: pain, paresthesia, and cranial nerve palsies from perineural spread

> “The clinical features depend on the site of the primary tumor and the nerve infiltrated.”
> “Tumors originating close to the skull base may cause ocular dysmotility, and cranial nerve palsies involving IX, X, XI, and XII. Cases of Horner's syndrome have also been reported.”
> “Depending on the region where the tumor originates, it can cause complications such as facial pain and paralysis, particularly if it involves the facial nerve.”

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)

> “Compared to non-HGT, the HGT cohort exhibited significantly higher rates of lymph node metastasis (39.1% vs. 8.7%; P < 0.05), perineural invasion (60.9% vs. 26.1%; P < 0.05), and increased Ki-67 proliferation index (35.0% vs. 10.0%; P < 0.05).”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.6-3"></a>

###### Sinonasal and nasopharyngeal symptoms: epistaxis and nasal obstruction

> “For instance, in the case of a nasopharyngeal tumor, frequent epistaxis and worsening nasal stenosis are seen along with dysfunction of the eustachian tube.”

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)

<a id="topic-2.2.1.6-4"></a>

###### Ocular symptoms: lacrimal gland ACC

> “Common presenting clinical features of lacrimal gland ACC include periorbital/periocular pain, globe dystopia, proptosis, and ‘S’-shaped ptosis.”

Source: [Pal et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12507167/)

<a id="topic-2.2.1.6-5"></a>

###### Respiratory symptoms: tracheal primary ACC

> “A total of 76 articles and 1252 cases were included in this review. The most common presenting symptom was dyspnoea (86.0%), followed by cough (58.0%).”

Source: [Ran et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7893857/)

<a id="topic-2.2.1.6-6"></a>

###### Regional lymph node metastasis

> “The incidence rate of neck metastases was 29%. The rate observed in the oral cavity is 37%, and in the major salivary glands is 19% (p = .001). The rate of occult nodal metastases was 17%.”

Source: [Amit et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4988229/)

> “The high propensity for lymph node metastases suggests a role for neck dissection in patients with this rare tumor.”

Source: [Seethala et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18059225/)

<a id="topic-2.2.1.6-7"></a>

###### Distant metastatic disease: lung, bone, and liver involvement

> “More than one-third of the cases progress to metastatic disease. The most common site of metastases via hematogenous spread is the lungs, followed by bone and liver.”

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)

> “The lungs are the most frequent site of metastasis, followed by the bone, lymph nodes, and liver”
> “Watchful waiting remains an option for asymptomatic patients with metastatic ACC who have a low tumor burden due to the low response rates and indolent course of the disease.”

Source: [Bölek et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12481798/)

> “NOTCH1 mutations define a distinct disease phenotype characterized by solid histology, liver and bone metastasis, poor prognosis, and potential responsiveness to Notch1 inhibitors.”

Source: [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/)

> “Solid type ACC showed a preponderance for multiorgan metastases (17/28; 61%).”

Source: [van Weert et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27775851/)

<a id="topic-2.2.1.6-8"></a>

###### Presenting symptoms and primary sites in high-grade transformation

> “The HGT group had a male-to-female ratio of 1:1.3 and a median age of 44 years (range 30–66 years). The sinonasal tract and lacrimal gland were the predominant tumor locations, accounting for 30.4% (7/23) of cases respectively.”
> “In the HGT group, 65.2% of participants initially displayed symptoms of dysfunction or paralysis related to the tumor location. In 13.0% (3/23) of cases, a painless mass was present, and in 17.4% (4/23), patients reported pain.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.1.6-9"></a>

###### Presenting symptoms by primary site

> “In the study of Nascimento et al.”
> “98% of patients reported a mass, 48% had pain, 30% had ulceration, and one patient had facial nerve paralysis; these symptoms had been present from 1 month to 4 years.”
> “The presenting symptoms of AdCC vary according to the site of disease. In major salivary glands the tumor produces a mass, and when located in the parotid, facial nerve palsy may occur; in the palate a mass is common, though ulceration or even oro-antral fistula may be seen; in the larynx dyspnea could be the first presenting symptom; in the nose and paranasal sinuses, nasal obstruction, deep facial pain, epistaxis and eye symptoms are at the forefront”

Source: [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)

<a id="topic-2.2.1.6-10"></a>

###### Lymph node metastasis rate in high-grade transformation compared with conventional ACC

> “The rate of metastasis to lymph nodes is ∼57% compared with only 5% to 25% in patients with conventional AdCC.”
> “The high propensity for lymph node metastasis, which is at least 5 to 10 times higher than for conventional AdCC, strongly supports neck dissection for patients with this unique histology.”

Source: [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/)

<a id="topic-2.2.1.6-11"></a>

###### Sites of metastatic sampling in a molecular profiling cohort

> “Most had ACC arising from the salivary glands of the head and neck (336, 77%), but other glandular subsites were also represented. Most samples were collected from metastatic sites (283, 65%), predominately from lung (95, 34%), liver (27, 10%), and bone (22, 8%).”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Summary: long-term morbidity

Long-term morbidity in ACC results from the tumor (perineural spread with facial pain, paralysis, and cranial neuropathies), from repeated local therapy for recurrences, and from the need for lifelong follow-up because distant metastases can occur more than 20 years after diagnosis. In a multinational study of 60 survivors of salivary gland cancer (all histologies) more than 5 years after diagnosis, the most frequently reported long-term problem was dry mouth (21 participants, about one third), and the most frequent grade 2 to 3 clinician-assessed toxicities were hearing impairment (13), soft tissue fibrosis (9), dry mouth (8), and cranial neuropathies (8). No study reporting long-term morbidity specifically for solid or high-grade ACC was identified.

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/); [Singer et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12703571/)

<a id="topic-2.2.1.7-2"></a>

###### Late toxicities and persistent symptoms in long-term salivary gland cancer survivors

> “Altogether, 60 survivors from nine countries participated and reported dry mouth (mean score 37.2), use of painkillers (35.0), problems with sexuality (30.1), insomnia (28.9), fatigue (27.8), trismus (24.9), and sticky saliva (23.3).”
> “The most frequent toxicities were hearing impairment, soft tissue fibrosis, dry mouth, and cranial neuropathies.”
> “The most frequently named was dry mouth, which was mentioned by a third of all participants (n = 21). The second‐most frequent were pain in the head and neck as well as difficulties swallowing, each mentioned by 10 survivors”

Source: [Singer et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12703571/)

<a id="topic-2.2.1.7-3"></a>

###### Treatment sequelae: facial nerve paralysis and functional impairment

> “Examples of known problems related to salivary gland tumor treatment include facial nerve paralysis”
> “hypo‐ and hyperesthesia, pain, dry mouth, dry eyes, swallowing problems, and fear of recurring disease”

Source: [Singer et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12703571/)

> “Apart from intraoperative surgical complications that occur during the removal of the tumor, the most common complication seen is the recurrence of the malignancy which is more commonly seen in patients with large, bulky tumors with lymphovascular infiltration and/or positive nodal status.”

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)

<a id="topic-2.2.1.7-4"></a>

###### Lifelong risk of late recurrence and metastasis

> “The latter is especially true for patients with adenoid‐cystic carcinoma; their risk of distant metastasis (primarily to the lungs) is high even after 20 years, so these patients may need life‐long follow‐up, much longer than is usual for head and neck cancer.”

Source: [Singer et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12703571/)

> “Additionally, while ACC may have a favorable short term outcome, it is a relentless disease with late recurrences and metastases, necessitating long-term follow-up”

Source: [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/)

> “Overall 10-year, 20-year, and 25-year survivals were 63.7, 27.3, and 20.0%, respectively. Similarly, disease-specific survival (DSSs) was 65.7, 51.2, and 38.4%, respectively, and disease-free survival was 25.2, 9.4, and 9.4%, respectively.”

Source: [Ishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330995/)

<a id="topic-2.2.1.7-5"></a>

###### Duration of follow-up required and late effects of local therapy

> “The clinical course is characterized by very late recurrences; consequently, clinical follow-up should extend at least >15 years.”
> “Unfortunately, local recurrences occur despite combined treatment with surgery and radiotherapy. Some authors postulate that postoperative radiation may delay rather than prevents recurrence”
> “Furthermore, severe late side effects of this approach include necrosis of the soft tissues, mandible, temporal bone and the temporal brain lobe, as well as cervical myelopathy and sensorineural hearing loss”

Source: [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)

<a id="topic-2.2.1.7-6"></a>

###### Pulmonary metastasis and surveillance requirements after high-grade transformation

> “Both HGT and non-HGT showed a high frequency of distant metastasis (78.3% vs. 52.2%), with the lungs being the primary metastatic site. Therefore, postoperative CT of the lungs should be performed as a standard follow-up assessment for patients with ACC, particularly for HGT patients who require close monitoring.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Adenoid cystic carcinoma with solid histology or high-grade transformation

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Summary: health-related quality of life

The only ACC-specific HRQoL study identified used the EQ-5D-5L in 161 participants (563 questionnaires, 2019 to 2023) at an experimental medicine center: median EQ-5D value was 0.81 (mean 0.79) and median visual analogue scale score was 70, and a decrease in value from 1 to 0 was associated with an eightfold increase in the risk of death. The mean value of 0.79 is below the age-matched general population mean of 0.86. Utility declined significantly over time, and adding NOTCH1 status, primary site, sex, age, recurrence status, or type of recurrence to the time model did not improve its fit, so no clinical predictor of decline was identified. In a 5-year prospective cohort of 252 participants with salivary gland cancer (all histologies), 41 (16.2%) had a declining quality-of-life trajectory and 79 (31.3%) had delayed recovery; recurrence, worse baseline pain, female sex, and older age were associated with unstable trajectories. The only interventional HRQoL data in recurrent or metastatic ACC come from the lenvatinib phase II trial, in which general quality-of-life scores fell by more than 10 points from baseline to 6 months for role functioning, global health, fatigue, pain, and diarrhea and by more than 10 points to 12 months for those domains plus physical functioning, social functioning, and appetite loss; head and neck scores fell by more than 10 points for sexuality, dry mouth, sticky saliva, coughing, and weight gain; EQ-5D-derived utilities ranged from 0.7 to 0.9 across the 12 months; and health status was below that of the general Italian population at every time point. No HRQoL data were identified separately for solid or high-grade transformation ACC.

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/); [Kang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41432961/); [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)

<a id="topic-2.2.1.8.1-2"></a>

###### EQ-5D-5L utility values and association with mortality in ACC

> “Between 2019 and 2023, 161 patients with ACC were identified who had completed at least one EQ-5D-5L questionnaire. A total of 563 EQ5D-5L questionnaires were completed with a median of two responses per patient (range 1 to 20).”
> “At the time of analysis, 41 % had died.”
> “These subgroups were well represented in this study, with 40 % local recurrence (14 % local recurrence only; 26 % local and metastatic recurrence) and 72 % metastatic recurrence (46 % metastatic recurrence only; 26 % both local and metastatic recurrence) for the 86 % of patients with recurrent disease (139/161).”
> “For all 161 patients, median EQV was 0.81 (range −0.22 to 1.0) and mean EQV was 0.79.”
> “For patients with ACC, a poorer QoL, as measured by EQ-5D-5L, was associated with a significantly increased risk of death. It remains unclear whether poorer QoL is a surrogate marker of increasing disease burden or whether there is a causal relationship with mortality. NOTCH1 status and pattern of disease recurrence were not associated with a poorer QoL in this cohort.”

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)

<a id="topic-2.2.1.8.1-3"></a>

###### Quality-of-life trajectories over 5 years after salivary gland cancer treatment

> “Among 252 participants, three QoL trajectories were identified: Stable Good (n = 132, 52.4%), Declining (n = 41, 16.2%), and Delayed Recovery (n = 79, 31.3%). Female sex, older age, worse baseline pain score, and recurrence were significantly associated with an unstable trajectory of QoL.”
> “The Declining group experienced deterioration in role, cognitive, and social functioning, along with increased fatigue, pain, and head-and-neck-specific symptoms.”

Source: [Kang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41432961/)

<a id="topic-2.2.1.8.1-4"></a>

###### Long-term quality of life in salivary gland cancer survivors

> “Dry mouth is a frequent and disturbing problem in SGC survivors.”

Source: [Singer et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12703571/)

<a id="topic-2.2.1.8.1-5"></a>

###### Patient counseling: risk of late recurrence and need for long-term follow-up

> “Upon diagnosis, the patient should be counseled regarding the slow-growing and locally aggressive nature of the tumor.”
> “The patient should, however, be educated about the possibility of recurrence of the malignancy even as late as more than 5 years after the initial surgery, so periodic medical follow-up should be reinforced.”

Source: [Ammad Ud Din and Shaikh (2023)](https://www.ncbi.nlm.nih.gov/books/NBK557855/)

<a id="topic-2.2.1.8.1-6"></a>

###### Quality-of-life instruments and assessment schedule in the lenvatinib phase II trial

> “The head and neck–specific EORTC QLQ-H&N35 module contains 35 items that can be condensed into 7 multi-item and 11 single-item scales. Both questionnaires result in scales that score from 0 to 100. For the function scales, a score of 100 indicates perfect QOL, whereas for the symptom scales it would indicate a heavy burden. A difference of 10 points is considered to approximately indicate minimal important clinical differences.”
> “Health status was measured using the EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L).”
> “We defined the following QOL domains a priori to be of primary interest for this study: Physical Functioning, Global Quality of Life, Fatigue, Swallowing, and Dry Mouth.”
> “These scores were calculated for baseline (t1), 3 months (t3), 6 months (t6), 9 months (t9), and 12 months (t12).”

Source: [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)

<a id="topic-2.2.1.8.1-7"></a>

###### Quality-of-life change over 12 months of lenvatinib treatment in recurrent or metastatic ACC

> “Changes in general QOL between baseline and t6 were >10 points for Role Functioning, Global Health, Fatigue, Pain, and Diarrhea. Changes between baseline and t12 were >10 points for Physical Functioning, Role Functioning, Social Functioning, Global Health, Fatigue, Pain, and Appetite Loss (Fig. 1).”
> “Head and neck–specific QOL deteriorated between t1 and t6 by >10 points in the domains of Sexuality, Dry Mouth, Sticky Saliva, Coughing, and Weight Gain (Fig. 2).”
> “Mean self-rated health was 67.3 at t1, 62.3 at t3, 62.3 at t6, 66.4 at t9, and 63.3 at t12. The utilities derived from the health profiles ranged from 0.7 (at t3) to 0.9 (at t9) (see Supporting Table 5). Compared with the general Italian population, the health status was found to be decreased at all time points (see Supporting Fig. 3).”

Source: [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)

<a id="topic-2.2.1.8.1-8"></a>

###### EQ-5D value score by decile in 161 participants with ACC

| Decile | EQ-5D value |
| --- | --- |
| Mean | “0.79” |
| 1st | “0.57” |
| 2nd | “0.68” |
| 3rd | “0.75” |
| 4th | “0.78” |
| 5th (median) | “0.81” |
| 6th | “0.86” |
| 7th | “0.88” |
| 8th | “0.92” |
| 9th | “0.94” |

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)

<a id="topic-2.2.1.8.1-9"></a>

###### EQ-5D-5L scale interpretation, visual analogue scale, and comparison with the age-matched general population

> “An EQV of 1 equates to perfect QoL, whilst an EQV of 0 is a state considered comparable to death.”
> “Median VAS was 70 (IQR 30 80).”
> “The mean EQV of 0.79 for patients with ACC is lower than the age-matched general population mean of 0.86”

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)

<a id="topic-2.2.1.8.1-10"></a>

###### Decline in quality of life over time and absence of clinical predictors

> “This is the first study to characterise the baseline QoL in the ACC population outside of an interventional clinical trial. We have demonstrated that QoL does significantly decrease over time in patients with ACC, but have identified no other significant risk factors for deteriorating QoL.”
> “Clinical variables including NOTCH1 status, location of primary site, sex, age, recurrence status and type of recurrence were evaluated by incorporating them into variant models, tested against the time model as a base (Table S1). No variant model with an additional clinical variable significantly improved the fit of the base model, suggesting the other variables do not have a significant impact on QoL (Table S1).”
> “No significant differences in QoL were observed between different patterns of recurrence; local recurrence was not demonstrated to have a significantly different QoL to metastatic recurrence, or both types of recurrence together. Furthermore, origin of primary site (major salivary glands or other sites) did not show a significant difference in QoL.”

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)

<a id="topic-2.2.1.8.1-11"></a>

###### EQ-5D-5L values reported in an interventional study of lenvatinib in ACC

> “Mean EQV at baseline was reported at 0.8, comparable with our findings, whilst they also found that QoL decreased over the study period of 12 months to a mean EQV of 0.7.”
> “However, the results of this study must be interpreted with caution as Locati et al only reported EQV to a single decimal place.”

Source: [Haigh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40753827/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Summary: economic burden

No cost-of-illness or healthcare resource utilization study specific to ACC or to aggressive ACC in the United States was identified. In United States administrative claims data (2005 to 2007 index dates) for 6,812 participants with oral cavity, oropharyngeal, or salivary gland cancer, total annual healthcare spending in the year after diagnosis was $79,151 in the commercially insured population, and spending exceeded that of matched comparators by payer type ($71,732 commercial, $35,890 Medicare, $44,541 Medicaid). Multimodality treatment cost twice as much as single-modality treatment, and employed participants had 44.9 more short-term disability days than comparators. In a German patient-level cost-effectiveness analysis in head and neck ACC, adding a carbon ion boost to IMRT increased overall costs by €18,076 with an ICER of €26,863 per life-year gained.

Source: [Jacobson et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3503554/); [Jensen and Debus (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6836331/)

<a id="topic-2.2.1.8.2-2"></a>

###### Direct and indirect costs of oral cavity, oropharyngeal, and salivary gland cancers in the United States

> “Total annual health care spending for OC/OP/SG patients during the year after the index diagnosis was $79,151 for the Commercial population. Health care costs were higher for OC/OP/SG cancer patients with Commercial Insurance ($71,732, n = 3,918), Medicare ($35,890, n = 2,303) and Medicaid ($44,541, n = 585) than the comparison group (all p < 0.01). Commercially-insured employees with cancer (n = 281) had 44.9 more short-term disability days than comparison employees (p < 0.01). Multimodality treatment was twice the cost of single modality therapy.”
> “Those patients receiving all three treatments (surgery, radiation, and chemotherapy) had the highest costs of cost of care, from $96,520 in the Medicare population to $153,892 in the Commercial population.”

Source: [Jacobson et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3503554/)

<a id="topic-2.2.1.8.2-3"></a>

###### Radiotherapy costs in head and neck ACC: IMRT with carbon ion boost

> “The experimental treatment increased overall costs by € 18,076 (€13,416 – €22,922) at a mean survival benefit of 0.86 years. Despite improved local control, following costs were also increased in the experimental treatment. The ICER was estimated to 26,863 €/LY.”
> “The combined treatment (IMRT+C12 boost) substantially increased initial and overall treatment cost.”

Source: [Jensen and Debus (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6836331/)

<a id="topic-2.2.1.8.2-4"></a>

###### Healthcare resource use: repeated treatment of recurrent and metastatic disease

> “DSS was significantly prolonged after salvage surgery for both locoregional recurrence (p = 0.004) and lung metastatic recurrence (p = 0.012, vs best supportive care).”

Source: [Ishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330995/)

> “A total of 51 patients were included in the study, of whom 36 (70.6%) received at least one line of systemic treatment.”
> “The median progression-free survival (PFS) was 7.82 months, 6.11 months, and 4.53 months for first-, second-, and third-line treatments, respectively. Disease progression was the primary reason for treatment discontinuation across all therapy lines.”

Source: [Bölek et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12481798/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Adenoid cystic carcinoma with solid histology or high-grade transformation on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Summary: economic impact on families

ACC is diagnosed mainly in adults (mean age at diagnosis 57.4 years in SEER; range 11 to 99 years), so family economic impact arises chiefly through caregiving and lost income rather than pediatric care. No study of caregiver or family costs specific to ACC was identified. In a pilot survey of participants with head and neck cancer at a United States comprehensive cancer center, high financial toxicity (COST score below 17.5) was reported by 25.9% of 27 patients and 44.4% of 9 caregivers. Among commercially insured employees with oral cavity, oropharyngeal, or salivary gland cancer, 281 participants had 44.9 more short-term disability days than matched comparators.

Source: [Ellington et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22294420/); [Nguyen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116977/); [Jacobson et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3503554/)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver financial toxicity in head and neck cancer

> “Research on financial toxicity has concentrated on patients despite many informal caregivers sharing finances and reducing work hours to provide patient care.”
> “Patients reported a median COST score of 27 while caregivers reported a median COST score of 16. Approximately 25.9% of patients and 44.4% of caregivers reported high financial toxicity (COST < 17.5). Caregivers reported high concerns about their future financial health and their ability to control the amount of their financial contributions to the patient's care.”

Source: [Nguyen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116977/)

<a id="topic-2.2.1.8.3-3"></a>

###### Work loss: short-term disability and return to work

> “Head and neck cancers are of particular interest to health care providers, their patients, and those paying for health care services, because they have a high morbidity, they are extremely expensive to treat, and of the survivors only 48% return to work.”

Source: [Jacobson et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3503554/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Summary: diagnostic testing costs

Identification of aggressive ACC relies on histologic assessment of the solid component and of high-grade transformation on routine histologic sections, supported by immunohistochemistry. Molecular subtyping by MYC and p63 immunohistochemistry uses stains available in standard clinical pathology laboratories. Ancillary tests used in ACC include MYB::NFIB FISH, MYB RNA in situ hybridization, and next-generation sequencing for NOTCH1 and other alterations; MYB immunohistochemistry has been described as an inexpensive alternative to FISH. No ACC-specific study of diagnostic testing costs was identified. As a reference price for comprehensive genomic profiling, the Medicare payment amount for FoundationOne CDx (0037U) during its new advanced diagnostic laboratory test initial period was $3,500.00.

Source: [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/); [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/); [CMS (2025)](https://www.cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)

<a id="topic-2.2.1.8.4-2"></a>

###### Immunohistochemistry for molecular subtyping: availability in routine pathology laboratories

> “Immunohistochemical detection of both MYC and P63 are commonly used in clinical histology laboratories making them ideal for clinical translation.”
> “A major strength of our study is that our proposed classification encompasses all ACCs, has a stronger prognostic value than disease stage and histological subtype, and of direct clinical relevance, the two biologically distinct subgroups can be largely differentiated by using standard immunohistochemistry staining available in any clinical pathology lab (P63/MYC)”

Source: [Ferrarotto et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854509/)

<a id="topic-2.2.1.8.4-3"></a>

###### MYB testing: relative cost of immunohistochemistry and FISH

> “MYB IHC was soon touted as an inexpensive practical alternative to FISH or other molecular testing.”

Source: [Bedell et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187024/)

<a id="topic-2.2.1.8.4-4"></a>

###### Comprehensive genomic profiling: Medicare payment for FoundationOne CDx

| Field | Quoted record |
| --- | --- |
| Test code | “0037U” |
| Test name | “FoundationOne CDx” |
| Test descriptor | “Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden” |
| New ADLT initial period | “7/1/18 - 3/31/19” |
| Payment amount for dates of service before initial period | “Contractor Priced” |
| Payment amount for dates of service during new ADLT initial period | “$3,500.00” |

Source: [CMS (2025)](https://www.cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)

<a id="topic-2.2.1.8.4-5"></a>

###### Commercial molecular profiling used to classify ACC-I and ACC-II

> “This retrospective observational cohort study involved de-identified samples from 438 patients with ACC with tumor samples sent for commercially-available molecular profiling (Caris Life Sciences).”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Surgical Resection and Metastasectomy

<a id="topic-2.2.2.1.1-1"></a>

###### ASCO guideline: revision resection and local ablative treatment of limited metastases

> “In the setting of resectable, recurrent locoregional disease and no distant metastatic disease, regardless of prior treatment type, patients should be offered revision resection and appropriate surgical reconstruction and rehabilitation.”
> “In the setting of resectable, recurrent locoregional disease and distant metastatic disease, regardless of prior treatment type, treatment may include palliative revision resection and appropriate surgical reconstruction and rehabilitation, if the metastatic disease is not rapidly progressive or imminently lethal.”
> “In the setting of ACC and/or low-grade tumors with indolent biology with limited metastases (ie, ≤5 metastases), local ablative treatments such as surgery (metastatectomy) or stereotactic body radiation therapy may be offered to delay local disease progression.”

Source: [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/)

<a id="topic-2.2.2.1.1-2"></a>

###### ESMO-EURACAN guideline: lung metastasectomy in selected patients

> “Lung metastasectomy should be considered in patients without other R/M tumour deposits, provided that a complete surgical resection is feasible and disease-free interval from primary diagnosis is >36 months.”
> “In one study, a prolonged disease-free interval (>36 months) and radical resection were the main prognostic factors in 109 patients with AdCC and lung metastases who underwent metastasectomy.”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

<a id="topic-2.2.2.1.1-3"></a>

###### Lung metastasectomy outcomes in 109 patients

> “The cumulative survival was 66.8% at 5years and 40.5% at 10years. In patients with a disease-free interval (DFI) greater than 36months, the overall survival was 76.5% at 5years. Survival in case of complete surgical resection was 69.5% at 5years.”
> “Lung metastasectomy should be considered as a therapeutic option to achieve local control of disease when 2 conditions are met: (1) complete surgical resection is feasible and (2) the time to pulmonary relapse after primary tumor treatment is greater than 36months.”

Source: [Girelli et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28341276/)

<a id="topic-2.2.2.1.1-4"></a>

###### Pulmonary metastasis-directed local therapy and overall survival: 219 participants

> “Of 219 included ACC, 119 (54%) had no PM‐LT and 100 (46%) did. PM‐LT patients had more nonsolid histology (p = .0008), oligometastases (p < .0001), exclusively PM (p = .02), and longer time to metastasis from diagnosis (p < .0001).”
> “On univariate and multivariate analysis, PM‐LT did not increase OS at any time point for nonsolid ACC.”
> “Findings suggest PM‐LT does not increase OS in unselected ACC.”

Source: [Hoff et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082800/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Radiotherapy

<a id="topic-2.2.2.1.2-1"></a>

###### ESMO-EURACAN guideline: re-irradiation and palliative radiotherapy

> “Local recurrence within the high-dose area following initial RT remains a challenge. When surgery is not an option, systemic treatments (either ChT or targeted agents) offer limited benefit with very moderate overall response rates and are therefore rarely successful in alleviating local symptoms.”
> “Based on these studies, re-irradiation with C12 appears feasible with response rates of around 60% and moderate toxicities in heavily pre-treated patients; however, C12 has limited availability in Europe.”
> “For patients with AdCC or AcCC and a WHO performance status score of 0-1, an even more prolonged RT schedule for palliation of locoregional disease or symptomatic distant metastases might be considered.”
> “Re-irradiation with C12 can be considered [IV, B]. Evidence is lacking to support the added value of proton treatment [V, C].”
> “There is currently no evidence to support the combination of re-irradiation and ChT for primary treatment of SGC [IV, C].”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

<a id="topic-2.2.2.1.2-2"></a>

###### ASCO guideline: radiotherapy for patients who are not surgical candidates

> “Radiotherapy should be offered to patients with SGM who are not candidates for surgical resection (because of extent of disease or medical comorbidity).”
> “Particle therapy, including proton, neutron, and carbon ion therapy, may be used for patients with SGM; there are no indications for the use of heavy particle therapy over photon or electron therapy.”

Source: [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/)

<a id="topic-2.2.2.1.2-3"></a>

###### Stereotactic body radiotherapy for oligometastatic ACC: SOLAR trial

| Field | Registry record |
| --- | --- |
| Brief title | “Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial” |
| Brief summary | “The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival.” |
| Cohort 1 eligibility | “One to five detectable sites of metastatic disease at any organ or site (including bone and CNS involvement)” |
| Overall status | “Recruiting” |

Source: [ClinicalTrials.gov NCT04883671](https://clinicaltrials.gov/study/NCT04883671)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Active Surveillance

<a id="topic-2.2.2.1.3-1"></a>

###### ESMO-EURACAN guideline: watch-and-wait in selected metastatic AdCC

> “To date, no systemic treatment has been shown to improve OS in patients with R/M AdCC.”
> “In this context, active surveillance could be a rational proposal in highly selected patients (asymptomatic, low tumour burden, lung metastases and stable disease).”
> “Systemic treatment should be reserved for patients with progressive and/or symptomatic disease that is not otherwise manageable.”
> “In case of only lung metastases without local recurrence, a watch-and-wait strategy is recommended until complaints or rapid growth (local treatment of lung metastases could be considered in selected cases) [III, B].”
> “In case of liver and/or bone involvement, there is a lower threshold to start (often more aggressive) systemic treatment [IV, C].”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

<a id="topic-2.2.2.1.3-2"></a>

###### ASCO guideline: criteria for initiating systemic therapy

| Recommendation 6.3 criterion | Quoted text |
| --- | --- |
| Stem | “Patients may be considered for initiation systemic therapy in the following circumstances:” |
| Criterion 1 | “metastatic deposits are symptomatic and not amenable to palliative local therapy,” |
| Criterion 2 | “growth has the potential to compromise organ function, or” |
| Criterion 3 | “lesions have grown more than 20% in the preceding 6 months.” |

Source: [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/)

<a id="topic-2.2.2.1.3-3"></a>

###### French REFCOR recommendations: active surveillance of polymetastatic ACC

> “At the metastatic stage, progression is often slow. In case of oligometastatic ACC, local treatment should be discussed. The most often indolent nature of polymetastatic ACC can allow management by active surveillance.”

Source: [Ferrand et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38061943/)

<a id="topic-2.2.2.1.3-4"></a>

###### Variable natural history of metastatic ACC

> “Once metastatic, the natural history can vary; some patients with indolent cancer remain asymptomatic for long periods, whereas others have rapidly progressive disease.”

Source: [Laurie et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21147032/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Multitargeted VEGFR Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### ASCO guideline: multitargeted TKI when a clinical trial is not available

> “For patients with ACC who are candidates for initiation systemic therapy, a multitargeted tyrosine kinase inhibitor (TKI), such as lenvatinib or sorafenib, may be offered if a clinical trial is not available.”

Source: [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/)

<a id="topic-2.2.2.1.4-2"></a>

###### ESMO-EURACAN guideline: angiogenesis inhibitors

> “When starting systemic treatment, consider angiogenesis inhibitors [III, C] or platinum-based ChT (i.e. CAP or doxorubicin–cisplatin) [III, B].”
> “Antiangiogenic agents (sorafenib, lenvatinib and axitinib) have been investigated in recent years, but response rates did not exceed 15%”
> “In this context, axitinib was the first agent to demonstrate a significant PFS prolongation compared with placebo in a phase II randomised trial (hazard ratio 0.25, 95% CI 0.14-0.48),”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

<a id="topic-2.2.2.1.4-3"></a>

###### NCCN Guidelines: lenvatinib and axitinib plus avelumab as category 2B options

> “Based on these results and lack of other evidence-based options for recurrent or metastatic adenoid cystic carcinoma, lenvatinib is a category 2B option.”

Source: [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml)

> “These results led to the inclusion of axitinib plus avelumab in the National Comprehensive Cancer Network (NCCN) guidelines as a category 2B recommendation for recurrent/metastatic ACC”

Source: [Hoff et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13404328/)

> “VEGFR-targeting tyrosine kinase inhibitors, such as lenvatinib and axitinib, have shown encouraging disease control rates and are now considered standard options.”

Source: [Galot and Machiels (2026)](https://pubmed.ncbi.nlm.nih.gov/41222550/)

<a id="topic-2.2.2.1.4-4"></a>

###### Lenvatinib: phase II trial in progressive R/M ACC

> “Thirty-three patients were enrolled; 32 were evaluable for the primary end point. Five patients (15.6%) had a confirmed partial response, 24 patients (75%) had stable disease, two patients (6.3%) discontinued treatment as a result of toxicity before the first scan, and one patient (3.1%) had progression of disease as best response.”
> “Median progression-free survival time was 17.5 months (95% CI, 7.2 months to not reached), although only eight progression events were observed.”

Source: [Tchekmedyian et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599407/)

> “Twenty-eight patients with R/M ACC were enrolled. Among 26 evaluable patients, 3 partial responses (11.5%) were reported.”
> “The median overall survival, progression-free survival, and duration of response were 27 months, 9.1 months, and 3.1 months, respectively.”

Source: [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)

> “Fifty-one patients were included across 17 Italian sites. Forty-six patients (90%) were evaluated for response: the ORR was 21.7%, with 10 patients achieving a partial response; 24 patients had a stable disease resulting in a disease control rate of 73.9%.”

Source: [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/)

<a id="topic-2.2.2.1.4-5"></a>

###### Axitinib: single-arm phase II trial and randomized phase II trial versus observation

> “Thirty-three patients were registered and evaluable for response. Fifteen patients had the axitinib dose increased. Tumor shrinkage was achieved in 22 (66.7%); 3 (9.1%) had confirmed partial responses.”
> “The median progression-free survival (PFS) was 5.7 months (range 0.92–21.8 months).”

Source: [Ho et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5035791/)

> “Sixty patients were allocated to the axitinib or observation group, with response evaluation conducted in 54 patients. With a median follow-up of 25.4 months, the 6-month PFS rate was 73.0% with axitinib and 23.0% with observation. Median PFS was longer in the axitinib arm (10.8 months vs. 2.8 months, P < 0.001). The ORR of axitinib was 0.0%, but the disease control rate was 100.0% with axitinib and 51.9% with observation. Median OS was not reached with axitinib, but was 27.2 months with observation (P = 0.226).”

Source: [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/)

<a id="topic-2.2.2.1.4-6"></a>

###### Axitinib plus avelumab: phase II trial

> “Forty patients enrolled from July 2019 to June 2021; 28 were evaluable for efficacy (six screen failures; six evaluable for safety only). The confirmed ORR was 18% (95% CI, 6.1 to 36.9); there was one unconfirmed partial response (PR).”
> “The median PFS was 7.3 months (95% CI, 3.7 to 11.2 months), 6-month PFS rate was 57% (95% CI, 41 to 78), and median OS was 16.6 months (95% CI, 12.4 to not reached months).”
> “The potential added benefit of avelumab to axitinib in ACC requires further investigation.”

Source: [Ferrarotto et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414730/)

<a id="topic-2.2.2.1.4-7"></a>

###### Rivoceranib (apatinib): RM-202 phase II trial

> “Eighty patients were enrolled and 72 were efficacy evaluable. Seventy-four patients had distant metastases and 49 received prior systemic treatment (14 received VEGFR TKIs). Per investigator and BIRC, respectively, ORR was 15.3% [95% confidence interval (95% CI), 7.9–25.7] and 9.7% (95% CI, 4.0–19.0); median duration of response was 14.9 months (95% CI, 4.9–17.3) and 7.2 months (95% CI, 3.5–8.4); and median progression-free survival was 9.0 months (95% CI, 7.3–11.5) and 9.0 months (95% CI, 7.7–11.5).”

Source: [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/)

<a id="topic-2.2.2.1.4-8"></a>

###### Apatinib: single-arm phase II trial in China

> “Among 68 patients treated with apatinib, 65 were evaluable for efficacy analysis, with a median follow-up time of 25.8 months. The 6-month, 12-month, and 24-month PFS rates were 92.3% [95% confidence interval (CI): 83–97.5%], 75.2% (95% CI: 61.5–84.0%) and 44.7% (95% CI: 32.3–57.5%), respectively. The objective response rate (ORR) and disease control rate (DCR), as assessed by investigators, were 46.2% (95% CI: 33.7–59.0%) and 98.5% (95% CI: 91.7–100.0%), respectively.”

Source: [Zhu et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8111556/)

<a id="topic-2.2.2.1.4-9"></a>

###### Sorafenib and dovitinib: phase II trials

> “Thirty-seven patients (19 adenoid cystic cancers, ACC) were enrolled. Six PRs were recorded. RR was 16% (95% confidence interval [CI]: 6-32; 11% in ACC and 22% in non-ACC).”

Source: [Locati et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27821319/)

> “The 4-month PFS probability was 80.4%, and the median PFS was 6.0 months (95% confidence interval, 4.4-7.6 months). Tumor shrinkage was observed in 22 patients (68.8%), and 1 patient had a confirmed partial response. The disease control rate was 96.9%.”

Source: [Keam et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25903089/)

<a id="topic-2.2.2.1.4-10"></a>

###### Meta-analysis of VEGFR inhibitors in R/M ACC: 17 studies, 560 participants

> “A total of 17 studies comprising 560 patients with recurrent or metastatic ACC treated with 10 VEGFR inhibitors were included. The objective response rate was 6% (95% CI, 3%-12%; I2 = 71%) and stable disease was the most frequent best overall response (82%; 95% CI, 74%-87%; I2 = 67%). The 6-month disease control (defined as objective response and stable disease) rate was 54% (95% CI, 45%-62%; I2 = 52%).”
> “Rivoceranib had the highest objective response rate (24%; 95% CI, 7%-57%) but high heterogeneity among studies (I2 = 95%) and the lowest rate of patients who continued therapy until PD (35%; 95% CI, 20%-55%; I2 = 90%).”

Source: [Hoff et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11140580/)

<a id="topic-2.2.2.1.4-11"></a>

###### Axitinib versus observation: randomized phase II efficacy results

| Outcome | Axitinib (N = 27) | Observation (N = 27) | Observation, after crossover (N = 26) |
| --- | --- | --- | --- |
| 6-month progression-free survival rate | “73% (52%–86%)” | “23% (9%–41%)” | “74% (51%–88%)” |
| Median progression-free survival, months | “10.8 (7.1–13.6)” | “2.8 (1.7–4.2)” | “14.5 (10.7–20.3)” |
| Hazard ratio for progression-free survival | “0.25 (0.14–0.48)” | | |
| Median overall survival, months | “NR (14.8–)” | “27.2 (20.2–32.8)” | |
| Hazard ratio for overall survival | “0.60 (0.26–1.38)” | | |
| Overall response rate | “0.0 (0.0–12.8)” | “0.0 (0.0–12.8)” | “11.5 (2.5–30.2)” |
| Disease control rate | “100.0 (87.2–100.0)” | “51.9 (31.9–71.3)” | “92.3 (74.9–99.1)” |
| Median follow-up, months | “31.9” | “28.4” | |

Source: [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/)

<a id="topic-2.2.2.1.4-12"></a>

###### Axitinib versus observation: trial design, eligibility, and response assessment

> “This study was an investigator-initiated, randomized, open-labeled, prospective phase II trial.”
> “Patients that were 20 years of age or over with pathologically confirmed recurrent or metastatic ACC, which was not appropriate to curative treatment, were eligible if they had experienced disease progression within the 9 months prior to the study.”
> “Prior use of cytotoxic chemotherapy, other than antiangiogenic inhibitor treatment, was allowed.”
> “Once disease progression was confirmed, patients in the observation arm were crossed over to axitinib treatment.”
> “The primary endpoint was the 6-month progression-free survival (PFS) rate, as determined by the investigators in accordance with RECIST 1.1”
> “The response evaluations were conducted via RECIST 1.1 and performed every 8 weeks until cancer progression. Tumor assessment was conducted every 8 weeks for both groups.”
> “Efficacy analysis was performed on a per-protocol basis. Non-evaluable patients were excluded from the per-protocol analysis.”

Source: [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/)

<a id="topic-2.2.2.1.4-13"></a>

###### Axitinib in salivary gland carcinoma including ACC: single-center phase II trial

> “This was a phase II, prospective, single-center, single arm trial with axitinib in patients with R/M SGCs not more amenable to curative options. One line of previous chemotherapy or TKI was allowed in patients with r/m non-ACC but not in ACC ones. Clinical or radiological progression of disease within 6 months of enrolment was required for inclusion.”
> “Primary end point was the assessment of activity of axitinib in terms of objective response rate (ORR) according to RECIST v1.1.”
> “Axitinib was administered at 5 mg twice a day (bid) (starting dose); in case of no AEs above grade 2 for a consecutive 2-week periods, the dose could be increased to 7 mg bid and further to 10 mg bid using the same criteria until tumor progression, unacceptable toxicity, or other criteria for discontinuation was met. Radiological assessments were performed at baseline and every 8 weeks.”
> “Twenty-six patients (50% were male; 6 ACC, 20 non-ACC) were treated. Response rate was 8% (2 partial responses), 13 stable disease (>6 months in 7 patients) and 11 disease progression. Median progression-free survival and overall survival were 5.5 and 26.2 months, respectively.”

Source: [Locati et al. (2019)](https://doi.org/10.1002/hed.25891)

<a id="topic-2.2.2.1.4-14"></a>

###### Sorafenib: phase II trial design, eligibility, and response assessment

> “Any number of prior therapies were allowed, including chemotherapy, other molecularly targeted agents, radiofrequency ablation, and radiotherapy.”
> “The study treatment was delivered as an out-patient and consisted of sorafenib 400 mg twice daily, taken orally on a continuous schedule.”
> “Response to treatment was evaluated radiologically, using MRI/CT for locally recurrent disease and/or CT for sites of metastatic disease at intervals of 4 months or on clinical suspicion of progressive disease, and classified according to RECIST 1.1 criteria.”
> “The primary purpose of this study was to determine PFS at 12 months in sorafenib-treated patients with advanced salivary ACC. Secondary purposes were to measure response rate (complete and partial responses), time to progression (TTP), OS, and to characterize the toxicity profile of sorafenib in this patient group.”

Source: [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577)

<a id="topic-2.2.2.1.4-15"></a>

###### Sorafenib: response and survival in advanced ACC of the head and neck

> “Twenty-three patients, median age 51 years, were recruited from 2009 to 2011.”
> “Median PFS and OS were 11.3 (95% confidence interval [CI], 8.9–13.7) and 19.6 (CI, 12.4–26.8) months, respectively”
> “Radiological response was not evaluable in 4 patients (17%) because of early discontinuation of sorafenib”
> “2 patients (11%) demonstrated a partial response (PR), 13 (68%) had stable disease, and 4 (21%) had progressive disease”
> “Both patients with PR showed reduction in disease at the primary site with stable disease elsewhere. Stable disease at 6 and 12 months was seen in 68% and 42% of patients, respectively.”

Source: [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577)

<a id="topic-2.2.2.1.4-16"></a>

###### Lenvatinib in real-world use: eligibility, starting dose, treatment duration, and clinical benefit

> “To be considered for the study, patients should be ≥ 18 years of age, have ECOG Performance Status (PS) 0–2, and histological diagnosis of ACC, with treatment using lenvatinib. Any prior line of systemic therapies, except lenvatinib, was allowed. Radiological images were internally reviewed with local radiologists, applying RECIST criteria.”
> “From August 2020 to January 2022, 51 patients were included across 17 Italian sites. The median follow-up was 10.8 months (95% CI 9.1–13.3). All patients had a progressive disease, either clinical or radiological, at the time of lenvatinib initiation.”
> “All patients received at least one dose of lenvatinib. Sixteen patients (31.37%) started treatment at the full dose of 24 mg daily, while all the others began with a reduced dose (Table 2). Among the 10 patients (19.6%) who started with a lenvatinib dose of 10 mg or less, 4 patients (40%) increased the dose by 4 mg during treatment. The median duration of therapy was 5.9 months (range 0.7–17.8+).”
> “Stable disease lasting longer than 6 months was observed in 16 subjects (34.8%). When these cases were combined with the 10 responders, a clinical benefit was observed in 56.5% of cases.”

Source: [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/)

<a id="topic-2.2.2.1.4-17"></a>

###### Lenvatinib phase II trial: enrollment, response detail, and clinical benefit rate

> “The current study was a prospective, single-arm, phase 2 trial performed at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, and examining lenvatinib at a dose of 24 mg daily administered to patients with R/M ACC until disease progression or unacceptable toxicity occurred.”
> “From June 2015 to August 2017, a total of 28 patients were enrolled.”
> “Approximately 21% of patients (6 of 28 patients) had extensive local disease with skull base involvement and/or disease close to the internal carotid artery. Two patients died before first disease reassessment due to rapid disease progression and were replaced by 2 other evaluable patients.”
> “Among the 26 patients who were evaluable for response, 3 patients achieved a partial response (11.5%), 20 patients had stable disease, and 3 patients experienced disease progression as their best response. No complete response was observed. Target lesion shrinkage between 23% and 28% was observed in 4 of 20 patients with stable disease (see Supporting Fig. 1). Clinical benefit (partial response and stable disease maintained for ≥6 months) was reported in 17 patients (65.4%). The median PFS and duration of response were 9.1 months (95% CI, 5.5-13.8 months) and 3.1 months (range, 1.8-30.7 months), respectively.”
> “The median time to response according to Response Evaluation Criteria in Solid Tumours (RECIST) was 5.4 months (range, 1.7-11 months).”

Source: [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)

Additional sources: [NCCN Guidelines Head and Neck Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Cytotoxic Chemotherapy

<a id="topic-2.2.2.1.5-1"></a>

###### ASCO guideline: chemotherapy combinations for symptomatic disease

> “Cytotoxic chemotherapy combinations may be offered to patients with symptomatic disease.”

Source: [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/)

<a id="topic-2.2.2.1.5-2"></a>

###### ESMO-EURACAN guideline: platinum-based regimens

> “A cisplatin-based regimen seems to guarantee the highest response rate: 13% with cisplatin alone and 25% (95% CI 11% to 39%) with CAP”
> “Duration of response ranges widely from 7 to 77 months. Carboplatin seems to have limited activity, and no response has been reported with paclitaxel or gemcitabine”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

<a id="topic-2.2.2.1.5-3"></a>

###### NCCN Guidelines: chemotherapy combinations as category 2B options

> “chemotherapy regimens such as these are acknowledged by the NCCN Guidelines Panel as treatment options for patients with advanced disease (category 2B)”

Source: [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml)

<a id="topic-2.2.2.1.5-4"></a>

###### Systematic reviews of chemotherapy response in ACC

> “Chemotherapy is generally reserved for the palliative treatment of symptomatic locally recurrent or metastatic disease that is not amenable to further surgery or radiation. Prospective trials of chemotherapy in advanced ACC are limited, and the optimum regimen is unclear.”
> “34 trials involving 441 patients are included.”

Source: [Laurie et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21147032/)

> “In 10 studies focusing on single agent chemotherapeutic treatment, only 22 out of 163 (16%) patients demonstrated objective responses.”
> “The combination of cisplatin, doxorubicin and cyclophosphamide (CAP) was the most common regimen for ACC, sometimes combined with 5-FU.”
> “In several studies, the combination therapy groups demonstrated greater toxicities, particularly nausea, vomiting, myelosuppression, and neuropathy.”

Source: [Sahara et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8493384/)

<a id="topic-2.2.2.1.5-5"></a>

###### Vinorelbine with or without cisplatin: randomized phase II trial in salivary gland malignancies

> “In Arms A and B a complete response (CR) was noted in 3 patients (19%) and no patients, respectively; a partial response (PR) was noted in 4 patients (25%) and 4 patients (20%), respectively; no change was noted in 6 patients (37.5%) and 9 patients (45%), respectively; and progressive disease was noted in 3 patients (19%) and 7 patients (35%), respectively.”

Source: [Airoldi et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11169936/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Investigational Therapies in Clinical Trials

<a id="topic-2.2.2.1.6-1"></a>

###### Guideline recommendations for clinical trial participation

> “Given the disappointing results of systemic treatments, participation in clinical trials is strongly recommended.”
> “In case of activated NOTCH mutation, participation in a NOTCH inhibitor clinical study is recommended, if possible [V, B].”
> “In case of R/M disease, consider sequencing (NGS) of the tumour [V, C].”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

> “ACCs are rare tumors for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials.”

Source: [Ferrand et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38061943/)

<a id="topic-2.2.2.1.6-2"></a>

###### NOTCH inhibitors: AL101 (ACCURACY) and brontictuzumab

| Field | Registry record |
| --- | --- |
| Official title | “A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations” |
| Primary outcome | “Overall Response Rate (ORR)” |
| Overall status | “Completed” |

Source: [ClinicalTrials.gov NCT03691207](https://clinicaltrials.gov/study/NCT03691207)

> “in a phase II trial with 82 patients with NOTCH‐mutated recurrent/metastatic ACC, AL101 produced a 69% disease control (PR plus SD) rate, and 12% of patients had a PR”
> “Twenty‐nine patients were included, with a predominance of solid histology (86%).”
> “BOR revealed partial response in 17% of patients, stable disease in 55%, and progressive disease in 28%. Median response duration was longer for AL101 compared to brontictuzumab (9.9 vs. 1.7 months, p  = 0.04). Median PFS with NOTCH inhibitor was 4.2 months (95% CI 2.7–8.6 months).”
> “However, limited PFS and progression of nontarget lesions suggest the potential need for combination therapy to address ACC heterogeneity.”

Source: [Hoff et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11872804/)

<a id="topic-2.2.2.1.6-3"></a>

###### B7-H4-directed antibody-drug conjugates: AZD8205 (puxitatug samrotecan) in ACC-I

| Field | Registry record |
| --- | --- |
| Brief title | “Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)” |
| Brief summary | “Phase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.” |
| Eligibility (ACC-I definition) | “Solid histology and clinical course characterized by < 3 years from diagnosis to initial recurrence or progression or de novo metastatic disease with extra-pulmonary metastasis” |
| Overall status | “Recruiting” |

Source: [ClinicalTrials.gov NCT07162480](https://clinicaltrials.gov/study/NCT07162480)

> “Two ACC-I/B7-H4-high PDXs obtained 90% complete responses to a single dose of AZD8205, but none were observed with isotype-conjugated payload or in an ACC-II/B7-H4 low PDX.”

Source: [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)

<a id="topic-2.2.2.1.6-4"></a>

###### Immune checkpoint inhibitors

> “For patients who are candidates for systemic therapy, checkpoint inhibitors should not be routinely offered at this time except for patients with selected molecular alteration (high tumor mutational burden [TMB], MSI-H).”

Source: [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/)

> “The primary efficacy endpoint (≥4 objective responses) was met in cohort 2 (5/32, 16%) but not in cohort 1 (2/32, 6%).”
> “This study shows that nivo+ipi has limited efficacy in ACC, albeit with infrequent, exceptional responses, and that it could be promising for non-ACC SGCs, particularly salivary duct carcinomas.”

Source: [Vos et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293616/)

<a id="topic-2.2.2.1.6-5"></a>

###### Emerging mechanism-based agents

> “New agents targeting oncogenic drivers, such as NOTCH1 mutations and epigenetic regulators like PRMT5, have demonstrated preliminary activity in early-phase clinical trials. Additional strategies, including B7-H4 targeted antibody-drug conjugates, MYB-directed vaccines and degraders, and MDM2 inhibitors for TP53 wild-type tumors, offer strong biological rationale for further development.”

Source: [Galot and Machiels (2026)](https://pubmed.ncbi.nlm.nih.gov/41222550/)

Additional sources: [Ferrarotto et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38118249/); [Hanna et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501326/); [Ferrarotto et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6009); [Ho et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.3089); [Hanna et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12947079/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary: limitations of local, surveillance, and systemic approaches in R/M ACC

No systemic therapy is approved by the FDA for recurrent or metastatic ACC, and the ESMO-EURACAN guideline states that no systemic treatment has been shown to improve overall survival. Guideline-endorsed systemic options (multitargeted VEGFR tyrosine kinase inhibitors and platinum-based chemotherapy) are supported by single-arm phase II trials and one randomized phase II trial, and NCCN lists lenvatinib and axitinib plus avelumab as category 2B options.

Objective responses are infrequent. A meta-analysis of 17 VEGFR inhibitor studies (560 participants) reported a pooled objective response rate of 6%, with stable disease as the most frequent best response (82%). Response rates were 15.6% with lenvatinib (32 evaluable participants), 11.5% in a second lenvatinib phase II trial (26 evaluable participants), 21.7% in a real-world lenvatinib cohort (46 evaluable participants), 9.1% with axitinib in ACC (33 participants), 8% with axitinib in a single-center trial in salivary gland carcinomas (26 participants), 0.0% with axitinib in the randomized trial versus observation, 11% with sorafenib (19 evaluable participants), 18% with axitinib plus avelumab (28 evaluable participants), and 9.7% by blinded independent review with rivoceranib (72 evaluable participants). Progression-free survival captures activity that the response rate does not: in the randomized axitinib trial the 6-month PFS rate was 73.0% with axitinib and 23.0% with observation and the disease control rate was 100.0% versus 51.9%, and median PFS was 10.8 versus 2.8 months (hazard ratio 0.25), yet neither arm produced a response and there was no statistically significant overall survival difference (P = 0.226), which the investigators attribute in part to crossover. Cytotoxic chemotherapy produced objective responses in 22 of 163 participants (16%) across single-agent studies and 25% with CAP, with greater toxicity for combinations.

Tolerability limits treatment duration and dose intensity. In the lenvatinib phase II trial reported by Tchekmedyian, 23 of 32 participants required dose modification and 18 of 32 discontinued for drug-related issues; in the Italian lenvatinib phase II trial, 96% had a treatment-related adverse event, grade 3 events occurred in approximately half of participants, dose reductions were required in 24 of 28, and 88% of first reductions occurred within 12 weeks. In the real-world lenvatinib cohort, every participant had a treatment-related adverse event, the most frequent grade 3 or higher events were hypertension (25.49%), stomatitis (17.65%), and fatigue (15.69%), 32 of 51 participants (63.6%) required a dose reduction, one fatal drug-related bleeding occurred, and only 16 of 51 (31.37%) started at the full 24 mg dose. With sorafenib, 13 of 23 participants (57%) had grade 3 toxicity and 74% required a dose reduction, and the investigators concluded that single-agent sorafenib could not be recommended for further evaluation. With axitinib in salivary gland carcinomas, all participants had a drug-related adverse event, grade 3 or higher events occurred in 12 of 26 (46%), median dose intensity was 59%, and the trial did not meet its primary endpoint. With rivoceranib, 70.0% had grade 3 or higher treatment-related adverse events and 85.0% required dose modification. The pooled dose reduction rate for VEGFR inhibitors was 59%. Because participants with recurrent or metastatic ACC often have few symptoms and prolonged life expectancy, even grade 1 to 2 adverse events can reduce quality of life, which deteriorated for fatigue and dry mouth by 6 months on lenvatinib.

Outcomes are worse in the aggressive subgroup targeted by emiltatug ledadotin. With axitinib plus avelumab, median PFS was 1.8 months in ACC-I versus 11.4 months in ACC-II, and in a real-world cohort ACC-I was associated with worse outcomes across pooled systemic treatment categories (HR 3.06). NOTCH inhibitors in NOTCH-activated disease (86% solid histology) produced a median PFS of 4.2 months. Pulmonary metastasis-directed local therapy did not increase overall survival in unselected patients, and active surveillance is recommended mainly for asymptomatic, low-burden, lung-only disease, which is less typical of solid or high-grade transformed ACC. Subtype-specific comparator evidence is otherwise scarce: the randomized axitinib trial did not capture detailed information on pathologic subtype, and the claims-based comparison of ACC-I and ACC-II by treatment type had limited sample sizes per treatment cohort and no information on clinical response.

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/); [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/); [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml); [Hoff et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11140580/); [Tchekmedyian et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599407/); [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/); [Locati et al. (2019)](https://doi.org/10.1002/hed.25891); [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/); [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577); [Ho et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5035791/); [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/); [Ferrarotto et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414730/); [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/); [Sahara et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8493384/); [Hoff et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13404328/); [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/); [Hoff et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11872804/); [Hoff et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082800/)

<a id="topic-2.2.2.1.7-2"></a>

###### No approved systemic therapy for R/M ACC

> “There is no systemic therapy for recurrent or metastatic adenoid cystic carcinoma (ACC) approved by the US Food and Drug Administration.”
> “The rate of grade 3 or higher adverse events was 53% (95% CI, 42%-64%; I2 = 81%) and of DRR was 59% (95% CI, 40%-76%). Most patients (57%; 95% CI, 44%-70%; I2 = 83%) continued therapy until PD; 21% (95% CI, 15%-28%; I2 = 62%) of patients suspended therapy for toxic effects.”

Source: [Hoff et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11140580/)

> “No systemic treatments are approved for use in R/M ACC in the United States or Europe. Cytotoxic chemotherapy typically results in low response rates and is often reserved for symptomatic or rapidly progressive disease (PD; refs. 1, 4).”

Source: [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/)

<a id="topic-2.2.2.1.7-3"></a>

###### Toxicity and quality of life with lenvatinib

> “Twenty-three patients required at least one dose modification, and 18 of 32 patients discontinued lenvatinib for drug-related issues. The most common grade 3 or 4 adverse events were hypertension (n = 9; 28.1%) and oral pain (n = 3; 9.4%). Three grade 4 adverse events were observed (myocardial infarction, n = 1; posterior reversible encephalopathy syndrome, n = 1; and intracranial hemorrhage, n = 1).”

Source: [Tchekmedyian et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599407/)

> “Treatment-related adverse events were frequent (all grades, 96%; grade≥3 in 50% of cases according to version 4.03 of the National Cancer Institute Common Terminology Criteria for Adverse Events).”
> “The QOL deteriorated between baseline and 6 months with regard to Fatigue and Dry Mouth.”

Source: [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)

<a id="topic-2.2.2.1.7-4"></a>

###### Toxicity with rivoceranib

> “Grade ≥3 treatment-related adverse events occurred in 56 patients (70.0%); the most common were hypertension (34, 42.5%) and stomatitis (6, 7.5%). Four grade 5 events occurred with one attributed to rivoceranib (epistaxis). Sixty-eight patients (85.0%) had ≥1 dose modifications and 16 patients (20.0%) discontinued rivoceranib for toxicity.”

Source: [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/)

<a id="topic-2.2.2.1.7-5"></a>

###### Stable disease as the predominant benefit of VEGFR-TKIs

> “Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.”

Source: [Kim et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11491249/)

<a id="topic-2.2.2.1.7-6"></a>

###### Axitinib in salivary gland cancer: primary endpoint not met, toxicity, and dose intensity

> “This trial did not meet its primary endpoint hence axitinib should not be considered for further investigations in SGCs.”
> “All patients had at least one drug related AE: stomatitis (69%), fatigue (58%), arterial hypertension (54%), diarrhea (50%), hypothyroidism (31%) and hand-foot syndrome (27%) were the most frequent. Grade ≥3 AEs”
> “were observed in 12 patients (46%): hypertension (31%) and weight loss (8%) were the most common TR AEs. Neither bleedings nor grade 5 AEs were observed.”
> “Median dose intensity was 59% (range 26%-100%).”

Source: [Locati et al. (2019)](https://doi.org/10.1002/hed.25891)

<a id="topic-2.2.2.1.7-7"></a>

###### Sorafenib: grade 3 toxicity, dose reductions, and trial conclusion

> “The median duration of sorafenib treatment was 11.8 months. However, it was only reasonably well tolerated and 13 patients (57%) experienced grade 3 toxicity. There were 25 grade 3 events (Table 4).”
> “A dose reduction was required in 74% of patients (12 of 23 patients were reduced to 600 mg and 5 of 23 to 400 mg) and only 6 of 23 patients did not receive this.”
> “However, sorafenib 400 mg twice daily was associated with significant toxicity. When considered together with limited effectiveness, single agent sorafenib cannot be enthusiastically recommended for further evaluation.”

Source: [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577)

<a id="topic-2.2.2.1.7-8"></a>

###### Lenvatinib in real-world use: grade 3 or higher adverse events and dose reductions

> “All patients were included in the safety analysis and experienced at least one TRAE of any grade (Table 4). The most common grade ≥ 3 TRAE were hypertension (25.49%), stomatitis (17.65%), and fatigue (15.69%). Thirty-two patients (63.6%) required at least one dose reduction due to adverse events. One fatal drug-related bleeding was reported after 6 months of lenvatinib treatment in a patient with lung metastases from a previous ACC of the right parotid.”
> “The rate of stomatitis > Grade 3 (17.65%) was unexpectedly higher than that reported in other studies”

Source: [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/)

<a id="topic-2.2.2.1.7-9"></a>

###### Lenvatinib phase II trial: dose reductions, serious adverse events, and discontinuation

> “Nearly all patients (96%) experienced at least 1 treatment-related AE (see Supporting Table 2). The median duration of treatment for the study population was 9.1 months (range, 2.4-36.1 months). Grade 3 AEs (grading was performed according to version 4.03 of the National Cancer Institute Common Terminology Criteria for Adverse Events) occurred in approximately one-half of patients, whereas no grade 4 and grade 5 toxicities were observed.”
> “The starting dose of lenvatinib was 24 mg. Dose reductions were required for 24 patients. Four patients maintained the full dose for a median of 1.7 months (range, 1.0-2.8 months). The first dose reduction occurred within 12 weeks from the initiation of therapy in approximately 88% of patients (21 of 24 patients)”
> “The median time to the appearance of any SAE was 9.6 months (range, 0.4-29 months). Hypertension was the earliest reported SAE at 0.4 months.”
> “In 2 responding patients (see Supporting Fig. 2), tumor shrinkage was complicated by the formation of an oral fistula that required the placement of a gastrostomy tube.”
> “Disease progression was the main cause of treatment discontinuation, occurring in approximately 88% of patients. Conversely, 1 patient discontinued treatment for unsustainable toxicity despite dose reductions (grade 2 asthenia and weight loss).”

Source: [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)

<a id="topic-2.2.2.1.7-10"></a>

###### Tolerability of multikinase inhibitors in a population with few symptoms

> “These patients generally experience few symptoms, and have a prolonged life expectancy despite the presence of R/M disease. In this scenario, there is major concern regarding the use of MKIs that may commonly induce side effects in an otherwise poorly symptomatic population. Within this context, even low-grade (grade 1 to grade 2) side effects might cause patients’ QOL to deteriorate.”

Source: [Locati et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32031693/)

<a id="topic-2.2.2.1.7-11"></a>

###### Axitinib: adverse events, dose reductions, and discontinuation compared with lenvatinib

> “The most frequently reported adverse event for the axitinib arm was grade 1 or 2 stomatitis (43.3%), with anorexia (33.3%) and proteinuria (33.3%) the next-most frequently reported AEs. The most frequent grade 3 AE was hypertension (23.3%).”
> “Eight patients (6 in the axitinib arm, 2 after crossover to axitinib in the observation arm) required at least one dose reduction.”
> “The dose intensity was 76.2% in the axitinib arm and 76.6% in patients who crossed over to axitinib in the observation arm.”
> “the response rate was 15.6%, and the median PFS was 17.5 months. However, 62.5% of patients had at least one grade 3 or 4 toxicity, and 18 patients (54.5%) discontinued treatment due to AEs. In this study, there was no grade 4 toxicity at all. In addition, only 6 patients in the axitinib arm (20.0%) discontinued treatment due to AEs.”

Source: [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated position of emiltatug ledadotin

Emiltatug ledadotin is investigational. Its anticipated population is locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation, the population named in the FDA Breakthrough Therapy designation. In current guidelines, systemic therapy for R/M ACC is started when metastases are symptomatic and not amenable to local therapy, threaten organ function, or have grown more than 20% in 6 months; clinical trial participation is the preferred option, followed by multitargeted VEGFR tyrosine kinase inhibitors or platinum-based chemotherapy. No agent is approved or designated as preferred, so emiltatug ledadotin, if approved, would enter a setting without an established first-line systemic standard. Based on the existing sequencing framework, it would most likely be used in progressive or symptomatic aggressive ACC, either before or after a VEGFR tyrosine kinase inhibitor; the ASCO 2026 interim analysis did not define a line of therapy, and the sponsor has stated that a pivotal phase 2 study is planned.

Emiltatug ledadotin is administered intravenously, which places it in a hospital-based or clinic-based infusion setting, in contrast with the oral VEGFR tyrosine kinase inhibitors. Given the rarity of ACC, guideline recommendations for management by multidisciplinary teams in specialized head and neck units apply.

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/); [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/); [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.2.2.2-2"></a>

###### Unmet need: no approved or preferred systemic therapy

> “Today there are no approved or preferred systemic therapies to treat advanced or metastatic ACC; most people are treated with surgery or radiation, but the disease recurs in 50 percent of cases, often becoming more aggressive with metastases in distant areas of the body”
> “It has also received Breakthrough Designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma with solid histology or high-grade transformation.”
> “will help inform the pivotal Phase 2 study we will undertake in a larger set of participants.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

> “Metastatic adenoid cystic carcinoma (ACC) remains a therapeutic challenge with no approved systemic standard of care.”

Source: [Galot and Machiels (2026)](https://pubmed.ncbi.nlm.nih.gov/41222550/)

> “Although recurrent/metastatic ACCs present with large biological heterogeneity, all patients are treated with VEGFR inhibitors (VEGFRi) or cytotoxic chemotherapy”

Source: [Hoff et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13404328/)

<a id="topic-2.2.2.2-3"></a>

###### Current sequencing framework for systemic therapy

> “Patients presenting with metastatic disease may be evaluated for further treatments such as local ablative treatments or systemic therapy. These options should be discussed with the patient and will depend on the patient and tumor factors.”
> “For patients with ACC who are candidates for initiation systemic therapy, a multitargeted tyrosine kinase inhibitor (TKI), such as lenvatinib or sorafenib, may be offered if a clinical trial is not available.”

Source: [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/)

> “Participation in clinical trials is strongly recommended [V, C].”
> “When starting systemic treatment, consider angiogenesis inhibitors [III, C] or platinum-based ChT (i.e. CAP or doxorubicin–cisplatin) [III, B].”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

<a id="topic-2.2.2.2-4"></a>

###### Care setting: intravenous administration

| Field | Registry record |
| --- | --- |
| Official title | “A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors” |
| Intervention description | “Emi-Le will be administered through a vein in your arm or port catheter (intravenously)” |
| Overall status | “Recruiting” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-2.2.2.2-5"></a>

###### Care setting: multidisciplinary management in specialized units

> “SGCs are a rare and complicated subgroup of head and neck cancers. As such, local/locoregional disease should be managed by expert surgeons, radiation oncologists, medical oncologists and other specialists working as a multidisciplinary team in specialised head and neck units, such as the centres that are designated members of the European Reference Network on Rare Adult Solid Cancers.”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary: factors that modify prognosis and treatment effect in R/M ACC

Molecular subtype and histology are the principal modifiers described. ACC-I, enriched for NOTCH1-activating mutations and MYC, has a median overall survival of approximately 3 years versus 23 years for ACC-II. NOTCH1-mutant tumors are associated with solid histology, liver and bone metastases, and shorter overall survival (median 30 versus 122 months). ACC-I tumors overexpress B7-H4, and B7-H4 expression is an independent predictor of poor survival; in patient-derived xenografts, the B7-H4-directed ADC AZD8205 produced complete responses only in ACC-I/B7-H4-high models.

With axitinib plus avelumab, objective response rates were similar in ACC-I and ACC-II (15% and 20%), but median PFS was 1.8 versus 11.4 months and progression as best response occurred in 62% versus 0%. In real-world data, ACC-I was associated with worse outcomes across systemic treatments (HR 3.06). High-grade transformation (solid pattern in 69.6%) was associated with distant metastasis in 78.3%. Solid histology was the strongest predictor of shorter survival after pulmonary metastasis. Among emiltatug ledadotin-treated participants, the objective response rate was 35.6% in all evaluable ACC (45 participants) and 46.9% in the post hoc aggressive ACC subgroup (32 participants), a comparison that is not randomized. With rivoceranib, investigator-assessed response rates differed by prior VEGFR inhibitor exposure (18.6% versus 0%), and bone metastasis was an independent poor prognostic factor with VEGFR-TKIs.

Most comparator studies did not analyze effect by subtype, and the modifiers they did examine were mainly clinical. The randomized axitinib trial found that mutation burden and MYB fusion did not correlate with response, progression-free survival, or overall survival, that FANCM and PCTH2 mutations were respectively positive and negative predictors of progression-free survival, and that it had not captured detailed information on pathologic subtype. In the real-world lenvatinib cohort of 51 participants, site of metastatic disease, including bone and liver, was not associated with activity, younger age was associated with a higher probability of disease control, and the higher response rate seen with a 24 mg starting dose was not statistically significant. In the sorafenib trial, 19 of 23 participants had documented progression at entry, and of the 4 with stable disease at entry none responded, which indicates that apparent benefit depends on whether progression is required for enrollment. In the axitinib trial in salivary gland carcinomas, the only responder with four mutated genes was a non-ACC tumor and best response was stable or progressive disease in all 6 tumors without recurrent mutations. The claims-based ACC-I and ACC-II comparison found similar survival with chemotherapy and with VEGFR tyrosine kinase inhibitors across subtypes, but had limited sample sizes per treatment cohort and no clinical response data. In high-grade transformation, therapeutic targets such as HER2 overexpression may be confined to the high-grade component, so biopsy of metastatic disease may be needed to confirm which clone the metastasis derives from.

Source: [Hoff et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13404328/); [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/); [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/); [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/); [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/); [Hoff et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082800/); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/); [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/); [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/); [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577); [Locati et al. (2019)](https://doi.org/10.1002/hed.25891); [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/); [Kim et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11491249/)

<a id="topic-2.2.2.3-2"></a>

###### Molecular subtype: ACC-I versus ACC-II outcomes with axitinib plus avelumab

> “Here, the median PFS was 1.8 months for ACC-I versus 11.4 months for ACC-II [hazard ratio (HR), 0.14; P < 0.0001)], representing the first demonstration of subtype-specific clinical trial outcomes in ACC.”
> “ACC-I is aggressive, is enriched for activating mutations in NOTCH1, and is associated with a median overall survival (OS) of 3 years, whereas ACC-II is more indolent and is associated with a median OS of 23 years (6).”
> “We found that although patients with ACC-I and those with ACC-II had similar ORRs (15% and 20%, respectively), patients with ACC-II had a higher rate of disease stabilization (80% vs. 15%), lower rate of disease progression as BOR (0% vs. 62%), and longer median PFS (11.4 months vs. 1.8 months, P < 0.0001).”
> “Taken together, these results suggest that patients with NOTCH1-activated tumors may derive less benefit from axitinib plus avelumab.”

Source: [Hoff et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13404328/)

<a id="topic-2.2.2.3-3"></a>

###### Molecular subtype: ACC-I outcomes across available systemic therapies

> “When pooling systemic treatment categories, ACC-I patients had worse outcomes with available therapies (HR, 3.06; 95% confidence interval, 1.65–5.68; P < 0.01), with no significant difference in overall survival between ACC-I/II based on chemotherapy or VEGFR tyrosine kinase inhibitor exposure in smaller subsets.”
> “When pooling all systemic treatments, MYC-high patients had worse outcomes with available therapies [HR, 1.68; 95% confidence interval (CI), 1.14–2.48; P < 0.05], whereas TP63-high patients had better outcomes (HR, 0.52; 95% CI, 0.34–0.80; P < 0.05; Fig. 3A and B).”
> “Patients with ACC-I (defined as MYC-high, TP63-low) had worse OS with any available systemic therapy (HR, 3.06; 95% CI, 1.64–5.68; P < 0.01)”
> “Survival outcomes are comparatively worse in ACC-I regardless of treatment type.”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.2.3-4"></a>

###### NOTCH1 mutations and solid histology

> “NOTCH1 mutations define a distinct aggressive ACC subgroup with a significantly higher likelihood of solid subtype (P < .001), advanced-stage disease at diagnosis (P = .02), higher rate of liver and bone metastasis (P ≤ .02), shorter relapse-free survival (median, 13 v 34 months; P = .01), and shorter overall survival (median 30 v 122 months; P = .001) when compared with NOTCH1 wild-type tumors.”

Source: [Ferrarotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5456373/)

<a id="topic-2.2.2.3-5"></a>

###### B7-H4 expression in aggressive ACC

> “ACC-I tumors overexpressed the immune checkpoint B7-H4, and the degree of immune exclusion was directly correlated with B7-H4 expression levels, an independent predictor of poor survival. Two ACC-I/B7-H4-high PDXs obtained 90% complete responses to a single dose of AZD8205, but none were observed with isotype-conjugated payload or in an ACC-II/B7-H4 low PDX.”
> “B7-H4 is highly expressed in poor-prognosis ACC-I subtype and is a potential therapeutic target.”

Source: [de Sousa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526680/)

<a id="topic-2.2.2.3-6"></a>

###### Emiltatug ledadotin: all ACC versus aggressive ACC subgroup

> “Promising signals of efficacy among 45 evaluable participants with ACC.”
> “Objective response rate (ORR) was 35.6%, including one complete response.”
> “Further, a post-hoc analysis was conducted in a more clearly defined aggressive ACC subtype reflecting clinical features used in practice by clinicians and pathologists, including solid histology or high-grade transformation.”
> “Consistent tumor shrinkage, with an ORR of 46.9%, DCR of 81.3% and median PFS of 7.8 months.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-2.2.2.3-7"></a>

###### High-grade transformation: clinicopathological features and outcomes

> “Notably, the solid subtype was the most prevalent pattern within HGT, accounting for 69.6% of cases.”
> “HGT was associated with increased recurrence (55.0%) and distant metastasis (78.3%), leading to an average survival of 35.9 months and a 3-years mortality rate of 35.0%. Overall and progression-free survival rates were significantly decreased in the HGT group.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.2.3-8"></a>

###### Solid histology and survival after pulmonary metastasis

> “The median OS from metastasis was significantly shorter for older patients (p = .003), males (p = .02), M1 disease at diagnosis (p = .03), solid histology (p < .0001), TTM less than 3 years (p = .02), DFI less than 3 years (p = .02), and presence of extrapulmonary metastases (p = .008)”
> “Given that ACC solid histology was the strongest predictor of poor prognosis in all multivariate survival analyses and was significantly more prevalent in the cohort who did not receive PM‐LT, we conducted a subgroup analysis of PM‐LT by histologic subtype.”

Source: [Hoff et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082800/)

<a id="topic-2.2.2.3-9"></a>

###### Prior VEGFR inhibitor exposure: rivoceranib

| Objective response, n (%, 95% CI) | Investigator | BIRC |
| --- | --- | --- |
| VEGFRi-naïve (59 evaluable) | “11 (18.6, 9.7–30.9)” | “5 (8.5, 2.8– 18.7)” |
| VEGFRi-treated (13 evaluable) | “0 (0, 0–24.7)” | “2 (15.4, 1.9– 45.4)” |

Source: [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/)

<a id="topic-2.2.2.3-10"></a>

###### Bone metastasis and genomic subsets with VEGFR-TKIs

> “In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response.”
> “Bone metastasis was an independent poor prognostic factor.”

Source: [Kim et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11491249/)

> “Analysis of MYB biomarkers and genomic profiling suggests the hypothesis that 4q12 amplified ACCs are a disease subset that benefit from TKI therapy.”

Source: [Ho et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5035791/)

<a id="topic-2.2.2.3-11"></a>

###### Randomized axitinib trial: genomic correlates and absence of pathologic subtype data

> “The mutation burden did not correlate with response, PFS, or OS. Furthermore, MYB fusion did not affect response, PFS, or OS. Mutations in FANCM were a positive predictive factor for PFS and mutations in PCTH2 were a negative predictive factor for PFS. Patients with SFB1, ARID1A, or BCOR mutations exhibited poor overall survival compared with others.”
> “Fourth, we did not capture quality-of-life data or detailed information regarding the pathologic subtype.”

Source: [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/)

<a id="topic-2.2.2.3-12"></a>

###### Lenvatinib real-world cohort: subgroups by age, prior therapy, metastatic site, and starting dose

> “The site of metastatic disease (e.g., bone and liver) was not associated with lenvatinib activity, while a younger age was associated with a higher probability of disease control.”
> “In patients with distant metastasis, no significant differences in ORR and DCR were observed between those with or without liver and bone lesions (Table 3).”
> “Although a higher response rate was observed in patients who started lenvatinib at 24 mg, we were unable to identify any statistically significant difference compared to those who started with lower doses (Table 3).”
> “This discrepancy may be attributed to the more compromised clinical characteristics of this real-world patient population, which included: (i) highly pre-treated patients (only 10% were treatment naïve for R/M disease); (ii) worse baseline general conditions (9.8% of patients with ECOG PS 2); (iii) only one-third of patients (31.37%) starting lenvatinib at the full dose.”

Source: [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/)

<a id="topic-2.2.2.3-13"></a>

###### Disease progression at enrollment as a determinant of apparent benefit

> “A potential criticism of this study is that radiological evidence of progressive disease was not a requirement at enrollment. On retrospective evaluation, 4 of 23 patients had stable disease on commencing sorafenib. Of these, none demonstrated an objective response and only 1 of 4 showed stable disease for >6 months.”
> “In support of this, at inclusion 19 patients (83%) had evidence of disease progression and of the 16 of 19 patients with evaluable disease, 12 (75%) showed stable disease at 6 months (Table 3).”

Source: [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577)

<a id="topic-2.2.2.3-14"></a>

###### Histology and mutation status of tumors responding to axitinib

> “Even though T-NGS was not feasible for all subjects, we observed that the tumor bearing the highest number (4) of mutated genes (deletions of TP53 and NOTCH1, single mutations of PIK3CA and JAK3) was the only non-ACC (a poorly differentiated carcinoma) responding to axitinib.”
> “Of note, best objective response was either SD or PD in all the six tumors without any recurrent mutations.”
> “Further investigations with antiangiogenic agents might be advisable in the ACC subgroup, where the activity of these agents is comparable to chemotherapy.”

Source: [Locati et al. (2019)](https://doi.org/10.1002/hed.25891)

<a id="topic-2.2.2.3-15"></a>

###### Chemotherapy and VEGFR inhibitor outcomes by subtype, and limits of the claims analysis

> “Further, although prior studies have observed higher response rates to cytotoxic chemotherapy among patients with ACC-I with more aggressive disease in practice, our results suggest similar survival between ACC phenotypes with the use of chemotherapy. Similar survival was also observed with the use of VEGFR TKIs across ACC-I and ACC-II subgroups, despite the upregulation of receptor tyrosine kinases in ACC-II, which are targets for VEGFR agents.”
> “Although we investigated important survival information for ACC-I and ACC-II subgroups by treatment type, the sample size for each treatment cohort was limited, and the use of insurance claims data relies on certain survival assumptions and did not include details of clinical responses to treatment.”

Source: [Hanna et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38416410/)

<a id="topic-2.2.2.3-16"></a>

###### Therapeutic targets confined to the high-grade component

> “Salivary carcinomas with HGT represent good candidates for genetic profiling for precise subtyping but also for detection of secondary genetic alterations of potential therapeutic relevance such as HER2 overexpression. In cases with potential therapeutic targets in the HG component such as those with HER2 overexpression, a biopsy of the metastatic disease might be of help to verify that the metastases are derived from the HG clone and not the LG component.”

Source: [Skálová et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33825717/)

Additional sources: [Siqueira et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12419983/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Summary: care management for R/M ACC and anticipated monitoring with emiltatug ledadotin

Guidelines recommend multidisciplinary management in specialized head and neck units, tumor sequencing at the time of recurrent or metastatic disease, and consideration of clinical trial participation, including NOTCH inhibitor trials for tumors with activating NOTCH mutations. Patients with residual, recurrent, or metastatic disease are imaged 2 to 4 times per year, with lower frequency when growth is slow, and systemic therapy is initiated on defined symptomatic or growth criteria. During VEGFR tyrosine kinase inhibitor therapy, dose modification is frequent (85.0% with rivoceranib; 23 of 32 participants with lenvatinib; 32 of 51 participants, 63.6%, in a real-world lenvatinib cohort), and hypertension, stomatitis, fatigue, and bleeding events require monitoring, including one fatal drug-related bleeding in the real-world cohort. For emiltatug ledadotin, the most common grade 3 treatment-related adverse events in the phase 1 analysis were AST increase (20%) and proteinuria (23%), which indicates a need for liver enzyme and urine protein monitoring; treatment-related adverse events led to discontinuation in 3.9% of participants.

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/); [Guideline Central (2021)](https://www.guidelinecentral.com/guideline/328512/); [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/); [Tchekmedyian et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599407/); [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-2.2.2.4-2"></a>

###### Imaging surveillance and multidisciplinary follow-up

> “Patients with residual/recurrent or metastatic disease should be scanned more regularly (i.e. 2-4 times per year), but when a low growth rate is present, the imaging frequency can be decreased [V, C].”
> “MRI scans are the best imaging tool for locoregional recurrent disease [V, C].”
> “A good multidisciplinary recovery programme is needed for every patient with SGC [V, B].”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

<a id="topic-2.2.2.4-3"></a>

###### Molecular testing to guide trial eligibility

> “In case of R/M disease, consider sequencing (NGS) of the tumour [V, C].”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

> “Molecular screening is recommended, for abnormalities potentially accessible to targeted therapy.”

Source: [Ferrand et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38061943/)

<a id="topic-2.2.2.4-4"></a>

###### Adverse event management during VEGFR tyrosine kinase inhibitor therapy

> “Toxicity was comparable to previous studies, requiring monitoring and management.”

Source: [Tchekmedyian et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599407/)

> “At least one treatment-related adverse event (TRAE) was recorded in all patients. The most frequent TRAEs of grade > 3 were hypertension (25.5%), stomatitis (17.6%), and fatigue (15.7%); one grade 5 TRAE (bleeding) was reported.”

Source: [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/)

> “Most common treatment-related adverse events (TRAEs) included fatigue (62%), hypertension (32%), and diarrhea (32%). Ten (29%) patients had serious TRAEs, all grade 3; four patients (12%) discontinued avelumab, and nine patients (26%) underwent axitinib dose reduction.”

Source: [Ferrarotto et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414730/)

<a id="topic-2.2.2.4-5"></a>

###### Emiltatug ledadotin: adverse events relevant to monitoring

> “Most treatment-related adverse events (TRAEs) were transient laboratory-based and/or low-grade. The most common TRAEs were transient AST increase (56%) generally asymptomatic and reversible proteinuria (54%), predominantly low-grade fatigue (42%) and nausea (33%).”
> “The only Grade 3 TRAEs in ≥10% of pts were transient AST increase (20%) and proteinuria (23%). No Grade 4 or 5 TRAEs reported.”
> “TRAEs leading to treatment discontinuation occurred in 3.9% of patients and no treatment-related deaths were reported.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

| Field | Registry record |
| --- | --- |
| Exclusion criterion | “Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.” |
| Exclusion criterion | “Prior B7-H4 targeted treatment.” |
| Exclusion criterion | “Active keratitis (inflammation of the cornea of the eye)” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary: benchmarks for outcomes in aggressive R/M ACC

The goals of systemic therapy in R/M ACC are tumor control, symptom palliation, and prolongation of progression-free survival, because no systemic treatment has been shown to improve overall survival. Survival benchmarks differ by subgroup: after pulmonary metastasis, median overall survival was 7.2 years in a cohort of 219 participants, whereas ACC-I has a median overall survival of approximately 3 years, and high-grade transformation was associated with an average survival of 35.9 months. After surgery and radiotherapy for high-grade transformation, median progression-free survival was 18.0 months compared with 37.0 months in matched non-transformed ACC. Treatment benchmarks include a pooled VEGFR inhibitor objective response rate of 6% and 6-month disease control rate of 54%; a 6-month PFS rate of 73.0% with axitinib versus 23.0% with observation and a median PFS of 10.8 versus 2.8 months in the randomized trial, with a median PFS of 14.5 months in participants who crossed over to axitinib after progression; a 6-month PFS rate of 69.3% and a 12-month rate of 46.2% with sorafenib, with median PFS of 11.3 months and median overall survival of 19.6 months; a median PFS of 14.8 months, a 6-month PFS rate of 75.7%, and a median overall survival of 16.1 months in a real-world lenvatinib cohort of 51 participants; and a median PFS of 1.8 months and median overall survival of 11.3 months in ACC-I treated with axitinib plus avelumab.

Against these benchmarks, the interim phase 1 analysis of emiltatug ledadotin reported, in 32 evaluable participants with aggressive ACC (solid histology or high-grade transformation), an objective response rate of 46.9%, a disease control rate of 81.3%, and a median PFS of 7.8 months. In the same post hoc subset, median duration of response was 6.4 months. At the earlier October 1, 2025 data cut-off, median overall survival had not been reached in participants with ACC. These are single-arm, post hoc, interim data, and quality of life outcomes have not been reported in the cited sources.

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/); [Hoff et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082800/); [Hoff et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13404328/); [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/); [Hoff et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11140580/); [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/); [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577); [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-2.2.2.7-2"></a>

###### Survival in R/M ACC overall

> “Despite these characteristics, survival of patients with R/M AdCC is generally prolonged, with an OS rate of 40% at 10 years”

Source: [van Herpen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9808465/)

> “Recurrent/metastatic (R/M) ACC is generally indolent with median survival exceeding 5 years; however, survival is shortened in those with distant metastases outside of the lungs and in those who require treatment within 3 years of R/M diagnosis”

Source: [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/)

> “For all 219 patients, the median OS from ACC diagnosis was 13.5 years (95% confidence interval [CI], 11–15.7), with a median follow‐up time of 14.8 years. The median OS from metastasis was 7.2 years (95% CI, 5.9–8.3), with a median follow‐up time of 9.3 years.”

Source: [Hoff et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082800/)

<a id="topic-2.2.2.7-3"></a>

###### Survival in aggressive ACC under current therapy

> “Additionally, we also found a statistically significant difference in the median OS between ACC-I (11.3 months; 95% CI, 6–NR) and ACC-II (36 months; 95% CI, 17.5–NR; HR, 0.25; 95% CI, 0.09–0.66; P = 0.01; Fig. 1D).”

Source: [Hoff et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13404328/)

> “HGT was associated with increased recurrence (55.0%) and distant metastasis (78.3%), leading to an average survival of 35.9 months and a 3-years mortality rate of 35.0%.”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

<a id="topic-2.2.2.7-4"></a>

###### Emiltatug ledadotin: reported efficacy in aggressive ACC

> “This analysis (n=32 evaluable participants) reported promising signals:”
> “Consistent tumor shrinkage, with an ORR of 46.9%, DCR of 81.3% and median PFS of 7.8 months.”
> “Disease control rate was 82.2%.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-2.2.2.7-5"></a>

###### Choice of endpoint: PFS versus objective response

> “Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.”

Source: [Kim et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11491249/)

> “Further investigation of rivoceranib in a placebo-controlled trial evaluating a time-to-event endpoint is warranted.”

Source: [Hanna et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10643996/)

<a id="topic-2.2.2.7-6"></a>

###### Overall and progression-free survival with lenvatinib in a real-world cohort

> “The median OS was 16.1 months (95% CI 12.2-NR) (Figure 1) and the median PFS was 14.8 months (95% CI 9.4–16.9) (Figure 2), with a six-month PFS of 75.7%.”
> “This is the largest cohort of ACC patients treated with lenvatinib to date in a real-life setting. Our study confirms the activity of lenvatinib observed in phase II studies.”

Source: [Caspani et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40033633/)

<a id="topic-2.2.2.7-7"></a>

###### Landmark progression-free and overall survival rates with sorafenib

> “PFS and OS at 6 months were 69.3% (CI, 46.1–84.1) and 82.6% (CI, 60.1–93.1), and at 12 months were 46.2% (CI, 25.1–65.0) and 73.9% (CI, 50.8–87.4), respectively”
> “The primary endpoint of this trial was to determine PFS at 12 months, which was seen in 46.2% of patients (CI, 25.1–65.0).”

Source: [Thomson et al. (2015)](https://doi.org/10.1002/hed.23577)

<a id="topic-2.2.2.7-8"></a>

###### Tumor shrinkage without objective response, and overall survival after crossover

> “The majority of patients on axitinib experienced tumor shrinkage (17 of 27 patients, 63.0%), and there was no partial response (PR) or progressive disease (PD) in this group (Fig. 2C).”
> “The median PFS of axitinib after crossover was 14.5 months (95% CI, 10.7–20.3 months; Table 2, per-protocol population; evaluable patients).”
> “No difference in OS was observed between the two groups, which might be attributed to the extensive crossover to axitinib in the placebo arm due to disease progression. It is difficult to conclude whether early use of axitinib is better than delayed use after progression; however, axitinib has been shown to induce a definite delay in progression and may thus be effective against symptomatic deterioration due to progression.”

Source: [Kang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34315722/)

<a id="topic-2.2.2.7-9"></a>

###### Outcomes achievable with cytotoxic and targeted systemic therapy

> “One may conclude that to date, systemic treatment employing cytotoxic chemotherapy or targeted molecular therapies does not yet result in patient cure with advanced (locally recurrent or metastatic) AdCC. At best, temporary partial disease response or stabilization may be achieved. Chemotherapy therefore should be reserved as a palliative treatment for patients with poorly controlled disease or affected with symptomatic metastases”
> “Moreover, the majority of AdCCs have a slow growth pattern, making it difficult to assess the efficacy of the particular systemic therapy, as objective tumor responses are uncommon”
> “Advances in therapeutic modalities have not had a significant impact on the natural history of AdCC of the head and neck.”

Source: [Coca-Pelaz et al. (2015)](https://doi.org/10.1016/j.oraloncology.2015.04.005)

<a id="topic-2.2.2.7-10"></a>

###### Progression-free survival after surgery and radiotherapy in high-grade transformation

> “The majority (73.9%; 17/23) of patients underwent surgery followed by radiotherapy.”
> “After a median follow-up of 29.0 months (range 6–108 months), the mortality rate was 47.8% (11/23), with an average survival of 35.9 months. The 3-year mortality rate was 34.8% (8/23), and the median PFS was 18.0 months (mean 25.1 months).”
> “In the non-HGT control group consisting of 23 patients, 73.9% (17/23) underwent surgery and radiotherapy.”
> “The 3-year mortality rate was 4.3% (1/23), and the median PFS was 37.0 months (mean 36.1 months).”

Source: [Ma et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38097822/)

## Related pages
- [Emiltatug ledadotin (Emi-Le): Adenoid cystic carcinoma with solid histology or high-grade transformation](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Terms and abbreviations](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/terms-and-abbreviations.md)
- [Emiltatug ledadotin (Emi-Le): Adenoid cystic carcinoma with solid histology or high-grade transformation](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/executive-summary) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/executive-summary.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Clinical evidence](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/clinical-evidence.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Economic information and modeling report](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/economics) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/economics.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: References](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/references) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/references.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: prevalence by geography](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/prevalence) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/prevalence.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/cost-effectiveness-analyses.md)
